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CHAPTER 1 
INTRODUCTION 
INTRODUCTION 
Renal transplantation is now a generally accepted procedure for the 
treatment of advanced chronic renal failure. Patient survival after 
transplantation has steadily increased especially as a consequence of 
the more judicious use of corticosteroids in the prevention and treat-
ment of graft rejection. After an initial improvement in the first 
years of transplantation, graft survival rates have remained stable in 
most centers during the last decade. When only patients who received a 
kidney from a cadaveric donor after 1978 are included, the one year 
patient and graft survival rates in the Sint Radboud Hospital were 92 
and 71 percent respectively. 
Most failures develop in the first three months after transplantation 
and 80 percent of the graft failures are caused by rejection . For im-
munosuppression, prednisone and azathioprine are the drugs most 
commonly used in these patients, but apparently this regimen cannot 
always prevent an acute rejection. More importantly, high doses of 
steroids are also not always sufficient to reverse an established 
rejection. To improve graft survival, more effective immunosuppressive 
agents are obviously required. This led us to evaluate the efficacy of 
antilymphocyte serum (ALS) in human renal transplantation. 
The notion that it might be possible to prepare a serum specifically 
active against one type of cell was first put forward by the great Rus-
sian zoologist Metchnikoff (1899)2, who used the material to 
investigate the cellular basis of inflammation. During the subsequent 
50 years animal studies layed the basis for most of our current 
knowledge of ALS, but it was not until Waksman and his colleagues-' 
demonstrated in rats that ALS suppressed delayed hypersensitivity 
responses, that its clinical use was actually considered. The 
application of the agent to organ transplantation, seemed a logical 
approach, particularly since there was growing evidence for an 
important role of lymphocytes in allograft rejection. In the years 
thereafter ALS proved to be remarkably effective in prolonging 
allograft survival in most animal models. An extensive survey of the 
effects of ALS in experimental animals was given by Lance et al^. 
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Despite a host of experimental studies the mechanism of the immunosup­
pressive activity of ALS is still unclear. ALS seems to exert its ac­
tion by inducing a depletion of peripheral blood Τ lymphocytes, but it 
is not known how this depletion actually occurs. Despite the fact that 
ALS can cause complement-mediated lysis of lymphocytes in vitro, there 
is no convincing evidence that the same mechanism is operative in 
vivo^. Results of animal studies suggest that circulating lymphocytes 
coated with ALS are efficiently opsonized by macrophages within the li­
ver and in lymphoid organs , . 
The clinical effectiveness of ALS has been even more difficult to eva­
luate. The reasons for this are many. Of course, there is a natural re­
luctance to inject large volumes of foreign protein into man because of 
the danger of allergic reactions. More importantly, however, it has 
been difficult to standardize the preparation of ALS. As a consequence, 
ALS preparations can differ widely in potency, and the situation is 
further complicated by the fact that this potency is very hard to eva­
luate, because in vitro tests that correlate with its in vivo effecti­
veness are not available. Prolongation of skin graft survival in mon­
keys is considered to be the only reliable parameter. Undoubtedly, 
these difficulties have led to the use of inadequate dosage schedules 
in several studies. There has been no general agreement on the species 
in which to raise the antiserum or on the type of antigen that would 
produce the most potent and least toxic antibody. In most centers that 
have tested ALS the number of patients treated (mostly a mixture of ca­
daveric and related transplantations) were insufficient to enable eva­
luation of the agent in a prospective randomized trial, and this led to 
multicenter trials with their inherent problems. Over the years several 
factors that are now known to influence graft outcome became apparent 
(blood transfusions, acute tubular necrosis, HLA typing, etc.). In the 
early studies with ALS no attempts were made to balance for these fac­
tors between test and control groups, which is a further complicating 
factor in the evaluation of the activity of ALS. In studies performed 
in the past, ATG has been almost exclusively used as an adjuvant immu­
nosuppressant, administered together with azathioprme and prednisone 
from the day of transplantation. Although a reduced incidence of early 
rejection episodes has usually been observed with such protocols, sig­
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nificant differences in long term survival rates between patients ran-
domly assigned to treated and control groups were only found in a few 
studies. 
The use of the abovementioned protocol was based on the assumption that 
ALS was especially effective in preventing the onset of an immune res-
ponse, but that it interfered less well with an ongoing response in ex-
perimental animals. It was, however, not completely ineffective in this 
regard, which made it worthwhile to investigate its effectiveness in 
the clinical situation. Over the last five years ALS has, therefore, 
been used by some groups for the treatment of acute renal graft rejec-
tion and in most studies the short term results were encouraging. Ob-
vious advantages of this approach as opposed to prophylactic treatment 
are that the agent is administered at the time it is most needed and 
that a considerable number of patients who never experience a rejection 
will not unnecessarily be exposed to the risks inherent to treatment 
with a foreign immunosuppressive protein. 
The initial results obtained with ALS in the treatment of acute rejec-
tions of renal grafts were encouraging enough to justify a systematic 
study. We have, therefore, started a prospective randomized trial in 
April 1979. This enabled us not only to obtain information on the ef-
fectiveness of ALS in the immediate reversal of acute rejections, but 
also to decide whether this new approach would have a beneficial in-
fluence on the long term survival of patients and grafts. 
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CHAPTER 2 
ALLOCATION OF PATIENTS TO TREATMENT GROUPS WHEN NOT ALL BALANCING 
FACTORS ARE KNOWN TO THE COORDINATING CENTER 
Henk JJ van Lier, Philip van Eiteren, Andries J Hoitsma, Robert AP 
Koene 
Reprinted by permission from 
Statistics in Medicine 19Θ4; in press 
Copyright 1984 John Wiley and Sons, Ltd. 
ABSTRACT 
The allocation of patients to treatment groups while balancing for risk 
factors is usually done by a coordinating center when all risk factors 
are known. In a clinical trial comparing two treatments of acute rejec-
tion of renal allografts some risk factors become available to the phy-
sician only at the moment of the diagnosis of the rejection. This diag-
nosis is often made out of office hours whereas immediate start of 
treatment is essential. It is shown here that the coordinating center 
is still able to control the allocation of patients to treatment groups 
if a small number of risk factors is only known to the physician. 
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THE PROBLEM 
In 1979 a single center clinical trial was started to study the effects 
of the treatment of first acute rejection of renal allografts occurring 
within three months after transplantation. Treatment with antithyroocyte 
globulin (ATG) was compared to conventional treatment with prednisone. 
The first results have been published elsewhere , . 
The trial had to conform to the following criteria: 
1. Patient and physician had to be kept unaware of the possible 
treatment prior to allocation. Ignorance after the allocation was 
not possible because ATG had to be administered by infusion and 
prednisone was given orally. This was also not necessary because the 
outcome of the treatment could not be influenced (graft failure). 
2. Patients had to be allocated to treatment groups while balancing for 
factors which might reflect the severity of the rejection or would 
influence the outcome of the treatment. The method of Taves3 was 
initially used for this purpose. 
This method consists of several steps and is equivalent to the range 
method of Pocock and Simon'*. At first, each risk factor is divided in 
categories. Then, in a table, here called the Taves scheme, the number 
of patients in both treatment groups and in each category of the risk 
factors are recorded. Freedman and White developed a simplified method 
that is followed here for the description of the next steps. At the en­
try of a new patient the Taves scheme is inspected with regard to the 
categories of this patient. Then the number of categories with an over-
representation of the first treatment (n·)) and with an underrepresenta-
tion (П2) are noted. Categories with an equal number of patients are 
left out. If n·) is smaller than П2 the new patient will be assigned to 
the first treatment group. If n·) is larger than П2 the patient will be 
assigned to the second treatment group. In case n·) equals П2 the new 
patient will be assigned with probability 0.50 to one of the treatment 
groups. 
In Table 1 the factors and their respective categories are listed that 
were considered to be of importance to establish the severity of the 
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Table 1 Balancing factors in a clinical trial comparing ATG and 
prednisone in treatment of acute renal allograft rejection 
Factor 
1 Age of patient 
2 Sex of patient 
3 Sex of donor 
4 Blood group patient 
5 Blood group donor 
6 Blood transfusions 
7 Previous transplants 
θ Renal osteodystrophy 
9 HLA-AB mismatches 
10 HLA-antibodies 
11 HLA-DR mismatches 
12 B-cell antibodies 
13 Interval transplantation 
to rejection 
14 Body temperature at day 
of rejection 
15 Dialysis within four days 
prior to rejection 
Categories 
« 40 / > 40 years 
male / female 
male / female 
0 / non-0 
0 / non-0 
none / 1 / 2 or more / 
unknown 
none /1 / 2 or more 
yes / no 
none / 1 on A-locus / 1 on 
B-locus / 2 or more 
none / « 50% / > 50% 
0 / 1 / 2 / unknown 
negative / positive / unknown 
< 12 / > 12 days 
< 37.2 / > 37.20C 
yes / no 
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rejection. Of the factors mentioned the first 12 are known from the 
date of the transplantation. Only the factors "interval transplantation 
to rejection", "body temperature at the day of rejection" and "dialysis 
within four days prior to rejection" become available at the time of 
diagnosis (rejection), but only to the physician. The coordinating cen-
ter that controls the allocation is only staffed during office hours. 
It was expected that the diagnosis would often be made late in the af-
ternoon. During weekends the coordinating center would also not be able 
to allocate patients to treatment groups. In the treatment of acute re-
jection it is essential that the treatment is started as soon as possi-
ble to minimize damage to the kidney. Therefore, it was expected that 
even during office hours the coordinating center would not be able to 
allocate patients on time. 
THE SOLUTION 
For this organizational problem the following solution was found: 
1. In the Taves scheme of the clinical trial patients with their 15 
risk factors are only admitted after the development of an acute re-
jection. 
2. For each of the eight combinations of the categories of the risk 
factors 13 to 15 of a transplanted patient whose risk factors 1 to 
12 are known (and who has not yet experienced an acute rejection) an 
allocation is performed without changing the Taves scheme. The re-
sulting treatments are stated in sealed forms and the coordinating 
center places these forms in a file on the transplantation depart-
ment. This is done for all patients immediately after the transplan-
tation. 
3. At the time of the diagnosis of the rejection the appropriate form 
of the patient is opened. The number of the patient, the actual risk 
factors 13 to 15 and the treatment group are passed on to the coor-
dinating center as soon as possible. 
4. The coordinating center updates the Taves scheme, repeats the proce-
dure at point 2 for all patients who have not yet shown signs of 
acute rejection and replaces the sealed forms. 
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5. If sealed forms are not available (e.g. in case of an acute rejec-
tion occurring soon after transplantation) the physician will open 
the envelope with the lowest number of a set of sealed and numbered 
envelopes. The envelopes contain cards indicating one of the two 
possible treatments chosen at random. 
6. When forms are made for a patient more than 12 days after the trans-
plantation the risk factor 13 (interval transplantation to rejec-
tion) is known. Thus, in these cases only four instead of eight 
forms are required. 
7. For each patient forms have to be made or changed during three 
months after transplantation. After this period patients are no lon-
ger admitted to the trial. 
EXAMPLE 
The above procedure is illustrated in a simplified situation with only 
four risk factors (6, 13, 14, 15). The first risk factor becomes avai-
lable on the day of the transplantation, the other three only at the 
moment of an acute rejection. We start from the situation that 17 pa-
tients have been allocated to the ATG group and 16 to the Prednisone 
group (for numbers of patients in the categories see Table 2). Forms 
must be made for a patient who has had two blood transfusions prior to 
the transplantation and whose transplantation has taken place more than 
12 days ago. 
In each category to which the patient belongs the difference is deter-
mined between the number of patients of that category who have been 
treated with ATG and those treated with prednisone. Subsequently, each 
of these differences is scored +1 when positive, 0 when zero, and -1 
when negative and the scores are added. If the sum of the scores is po-
sitive the new patient will be allocated to the Prednisone group and, 
in the case of a negative sum, to the ATG group. Should the sum be ze-
ro, the patient will be allocated at random to a treatment group with 
probability 0.50. If at the day of rejection the new patient has a bo-
dy temperature of 37.2°C or less and has been dialyzed, then the sum of 
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Table 2 Example with risk factors 6, 13, 14, and 15 
Numbers of patients already allocated to each treatment group 
and scores of the differences 
Factor 
6 Blood trans­
fusions 
13 Interval trans­
plantation to 
rejection 
14 Body temperature 
at day of 
rejection 
15 Dialysis within 
four days prior 
to rejection 
Category 
0 
1 
2 or more 
unknown 
$ 12 days 
> 12 days 
« 37.20C 
> 37.20C 
yes 
no 
Number 
A* 
1 
13 
3 
0 
9 
β 
11 
6 
2 
15 
of patients 
P* 
2 
11 
3 
0 
7 
9 
9 
7 
1 
15 
Diff.* 
-1 
2 
0 
0 
2 
-1 
2 
-1 
1 
0 
Score 
-1 
+ 1 
0 
0 
+ 1 
-1 
+1 
-1 
+ 1 
0 
Total 17 16 
A = ATG group, Ρ = Prednisone group, Diff 
patients in ATG and Prednisone group 
difference in number of 
21 
the scores will be positive and the patient will receive prednisone. 
This treatment is then stated in the sealed form for this particular 
situation. Table 3 shows the four combinations of categories and the 
contents of the forms for the patient considered. 
DISCUSSION 
The method described here was mainly developed because in the clinical 
trial considered three risk factors could not be made available to the 
coordinating center on time. The risk factor "interval transplantation 
to rejection" has often been reported to be of prognostic value"/ . 
There is a clear indication that rejections occurring soon after trans-
plantation are more serious and often become irreversible. The risk 
factor "dialysis within four days prior to rejection" was taken into 
account because diagnosis of an acute rejection and patient management 
are much more difficult after dialysis. The risk factor "body tempera-
ture at day of rejection" is less well established, but the authors 
have a strong indication that patients with a high body temperature 
have a more severe rejection. 
These three factors with the risk factors already known at the day of 
the transplantation had to be distributed equally in both treatment 
groups. At first, the method of Taves-* was used for this purpose. Non-
balancing allocation methods like simple randomization were discarded 
because differences in numbers of patients would easily become too 
large, especially for analyses to be performed in subgroups (in sub-
groups of 20 patients the probability is more than 0.01 that a treat-
ment group contains four or fewer patients; in subgroups of 40 patients 
this figure is 12). 
After the publication of the paper by Begg and Iglewicz the same simu-
lations were performed also using the standardized variance method, an 
obvious extension of the variance method of Pocock and Simon4. With the 
variance method the scores are multiplied by the absolute difference in 
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Table 3 Scores and contents of forms in example for a patient with two 
blood transfusions and an interval after transplantation of 
more than 12 days 
Combination 
Factor Category 1 2 3 4 
6 Blood transfusions 2 or more 0 0 0 0 
13 Interval transplantation > 12 days -1 -1 -1 -1 
to rejection 
14 Body temperature at day « 37.20C 1 1 
of rejection > 37.20C -1 -1 
15 Dialysis within four yes 1 1 
days prior to rejection no 0 0 
Sum of scores 1 0 -1 -2 
Content of form P* C* A* A* 
* A = allocation to ATG group, Ρ = allocation to Prednisone group, 
С = allocation to treatment groups at random with probability 0.50. 
The resulting allocation is stated inside the form. 
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the categories, and greater weight is given to larger differences. With 
standardization the scores are also divided by the number of patients 
in the categories, and greater weight is given to small subgroups than 
to large subgroups. The simulations revealed the smallest imbalances in 
the categories and in the total number of patients for the standardized 
variance method. Therefore the actual allocation method was changed ac-
cordingly. The scores were also multiplied by a positive number that 
was larger for risk factors that were expected to have greater influen-
ce on the outcome of the treatment. Neither change did affect the ap-
plicability of the allocation procedure described in this paper, but 
would unnecessarily complicate the presentation. 
Meier^ states as an objection to the use of balancing allocation me-
thods that it is sometimes difficult or impossible to classify a pa-
tient prior to treatment and mentions the problems arising from a wrong 
classification (should the patient be reassigned to the right category 
or not?). By using the method proposed in this paper the risk of a 
wrong classification is reduced. This method can be used when the time 
between the diagnosis or the measurement of risk factors and the 
commencement of the treatment is short. It is most easily applied when 
at the moment of diagnosis few risk factors need to be introduced 
whereas the remaining risk factors have already been measured at an 
earlier stage. Such a situation not only occurs during renal allograft 
rejection but also in heart operations (e.g. the risk factor "extent of 
occlusion in a coronary artery" can not be determined accurately by 
angiogram prior to the operation but becomes available during the 
operation) and operations for the removal of tumors (e.g. size and 
stage of the tumors). If there are many unknown risk factors, however, 
this method will soon become impractical. 
A problem that one may encounter is the situation in which many pa-
tients are in the interval between transplantation and rejection. Allo-
cation methods like the method of Taves and the (standardized) variance 
method have the property that the numbers of patients in both treatment 
groups are nearly always equal. When an imbalance in the total number 
of patients exists the allocation of the next patient will almost sure-
ly counteract this imbalance. In that case the same treatment will be 
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stated in the sealed forms of many patients. If the physician has to 
open forms for second and following patients before he can contact the 
coordinating center, he will often be able to predict to which treat-
ment group these patients will be allocated. This would seriously in-
crease the possibility of selection bias. This problem is not likely to 
occur in our clinical trial with one or two transplantations a week and 
a probability of acute rejection in the first three months of 0.60 to 
0.70. However, should this situation occur regularly, then the use of 
the sealed and numbered envelopes (i.e. simple randomization) for se-
cond and following patients is recommended. Because these patients are 
subsequently admitted to the Taves scheme any possible lack of balance 
can generally be compensated for afterwards. 
In our clinical trial four to six patients were concomitantly at risk 
for an acute rejection. For preparing, sealing and placing the forms an 
average time of 30 to 60 minutes a week was required, because a compu-
ter was used to update the Taves scheme and to print the forms. The use 
of a personal computer by the physician would circumvent a procedure as 
described here, but would also increase the possibility of selection 
bias by the physician and require the training of the physicians and 
other members of the staff of the transplantation department. 
It is obvious that in a multicenter clinical trial the coordinating 
center has to pass information to all local coordinating units after 
each rejection. These local units should be equiped with adequate 
printing facilities. The procedure described so far is rather time con-
suming. In clinical trials with a large number of patients or a large 
number of unknown risk factors the following adaptation might be consi-
dered. Two sets of sealed and numbered envelopes are available at every 
transplantation center, the first one containing cards indicating one 
of the two treatments chosen at random, the second one containing cards 
with "yes" or "no". The number of yes cards has to be larger than the 
number of no cards. After each rejection in the clinical trial a sealed 
form is (re-)placed at every transplantation center containing the num-
ber of patients in the categories (the Taves scheme) or the scores. 
When a rejection occurs at a center, the physician opens this sealed 
form and performs the calculations required for the allocation proce-
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dure. In the case of no imbalance an envelope is taken from the first 
set. When a treatment is underrepresented an envelope is taken from the 
second set. If the card indicates yes the patient will be allocated to 
this prescribed group. Otherwise, he will be allocated to the other 
group. The risk factors and the treatment group are passed on to the 
coordinating center as soon as possible. This adaptation reduces the 
number of forms to be made by the local coordinating units or the coor-
dinating center. However, it requires some arithmetic by the busy phy-
sician and enlarges the knowledge of the physician about the state of 
the clinical trial. To prevent selection bias the number of yes cards 
has to be chosen very carefully, but the imbalances in the categories 
and in the total number of patients are likely to increase with fewer 
yes cards. 
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TREATMENT OF ACUTE REJECTION OF CADAVERIC RENAL 
ALLOGRAFTS WITH RABBIT ANTITHYMOCYTE GLOBULIN 
A N D R I E S J H O I T S M A P A U L R F E K E R S J O H A N G K R E E F T F N B E R G H E N K J J VAN L I E R 
P F T F R J A C A P E L A N D R O B E R T A Ρ K O F N F 
Department of Medicine Dntsion of Nephrologv I aboratory of Transplantation Serology and Statistical Support Center Smf 
Radboudziekenhui\ I nuersity of \ijmegen and Rijksinstituut ι oor de Volksgezondheid Bilthoten The Netherlands 
In a prospective randomized single-blind tnal, we com­
pared the effectiveness of rabbit antithymoc>te globulin 
(RATG) ш the treatment of acuti renal graft rejection 
with the results of treatment by high oral doses of pred­
nisone Twenty recipients of cadaveric kidneys were 
included in each group In the RATG group, the prcdm 
sone dose was not increased and a dose-by rosette pro­
tocol was used to keep Τ cell levels between 50 and 150/ 
mm
3
 In this group 15 of the 20 patients responded to the 
treatment One of these patients lost her kidney after­
ward because of a technical failure In five patients 
rejection was irreversible despite a subsequent course of 
high-dose prednisone orally In the prednisone group, 11 
patients showed a good response, but 3 of them only 
after a subsequent course of RATG The remaining seven 
patients underwent ncphrectom> before a course of 
RATG could be given One patient in this group died of 
septicemia In either group there were six second rejec­
tion episodes, but they developed 2 2 months later in the 
RATG group All second rejection episodes were treated 
with the alternative regimen and all patients responded 
to this treatment Renal function after 6 months was 
similar in both groups Less infections occurred in the 
RATG group Prior to rejection, there were no differ 
enees in concentrations of peripheral Τ cells between 
both groups Treatment of acute rejections with RATG 
is an effective and safe procedure which is steroid spar 
mg 
The question whether treatment w ith antithvmocyte globulin 
improves kidnev graft survival in man is still a matter of debate 
Recent results of Thomas et al (1) have shown that the efficaí \ 
of antithvmocvte globulin (ATG) depends on its potency as 
measured by prolongation of skin graft survival in primates 
Furthermore there is evidence that the source of AT G is also 
of importance equine Al G being less immunosuppressive than 
RATG (2) In most trials the administration of ATG is started 
immediately after transplantation whereas high doses of ste 
roids are administered when rejection occurs There are onlv a 
few reports on the effica* ν of АТС» treatment started at the 
time of acute rejection and again the available data are con 
flicting Two studies (3 4) showed no benefit of this form of 
treatment whereas in two others the only advantages were the 
occurrence of fewer second rejection episodes (5) and a more 
rapid reversal of rejection (6) A recent study showed for the 
first time a better graft survival in patients treated with A I G 
for their rejection (7) However these results are somewhat 
difficult to assess since in all studies mentioned ATG was 
administered in addition to standard treatment of rejection 
with high doses of steroids Shield et al (8) were the first to 
show the effectiveness of ATG when added at the time of 
rejection without a concomitant increase of the steroid dosage 
In this study onlv recipients of related donor kidne\s were 
included Hardy et al (9) added ATG when rejections were not 
responsive to a Í to "> dav tourse of standard antirejection 
treatment and found a better graft survival in the AT G treated 
group as compared with a control group All of the ATG 
preparations that were used in the above mentioned trials were 
of equine origin and therefore probably of moderate or low 
potcnev 
W e hav e tried to obv late some of the difficulties encountered 
in previous investigations by using a high potency RATG as 
the single pgent in the treatment of first rejections of cadavenc 
grafts and by comparing the results m a randomized trial with 
the effects of high oral doses of prednisone 
M VI l· RIALS AM) MFTHODS 
Fortv recipients of a cadavenc renal allograft who expen 
enced a rejection episode were included in our trial Related 
donors and diabetic patients were excluded Only patients with 
first rejection episodes withm Ì months after transplantation 
were admitted to the protocol Twent> eight recipients who did 
not experience a rejection within the first 3 months served as 
an additional control group Acute rejection was diagnosed 
ac cording to the standard criteria (increase of serum с reatmine 
sodium retention oliguria weight gain hypertension protein 
una tenderness of the graft) Biopsies were onlv done when 
second rejection episodes occurred Twenty patients were 
treated with RA TG and 20 received high doses of steroids 
orallv RATG that was prepared in the Rijksinstituut voor de 
Volksgezondheid according to the method described b> Kreef 
tenberg (2) induced a skin graft survival of 20 to Ю days in 
c\ nomolgus monkev s whereas the surv ival time was 7 to 8 days 
in untreatc d -mimais A commercial horse ATG preparation 
(A I GAM the Lpjohn С ompanv) induced a graft survival of 10 
to 11 da\s in this model In rhesus monkeys skin graft survival 
with RATG was 50 da>s For the allocation of the patients to 
the different treatment groups the minimization method of 
Tavts (70) was used balancing the following variables (with 
different weights) sex age blood group of the recipient number 
of blood transfusions number of mismatches for HLA A В 
and DR antigens presence of Ivmphocvtotoxic antibodies and 
В cell antibodies number of previous transplants time of onset 
of the acute rejection after transplantation and body temper 
ature at the dav of diagnosis Until the diagnosis of acute 
rejection was made all patients were treated similarly predni 
sone was started on the day of transplantation in a dose of 100 
mg dail\ and tapered in penods of 5 days to 75 50 40 30 and 
25 mg The azathiopnne dose was 1 5 mg/kg bod> wt when the 
creatinine clearance was less than 25 ml/min and 3 mg/kg at 
higher clearances The dose was also decreased when the leu 
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kocyte count was less than 4000/mm ' or when the thrombocytes 
were less t h a n JOO.OOO/mm' In the RATO group t h e acute 
rejection was t reated with a 3-week course of RATG ι ν T h e 
initial dose was 4 mg/kg and additional doses were between 2 
and 7 mg/kg with a totaJ frequency that vaned from three to 
nine doses, depending on the peripheral Τ cell level t h a t we 
tried to keep between 50 to 150/mm 1 (11) T h e prednisone dose 
was not raised in the RA'I G group, except for the addition of 
50 mg of prednisolone to the first and 25 mg to each following 
RATG infusion to avoid acute side effects In the prednisone 
group t h e oral dose of prednisone was raised to 200 mg/dav 
when acute rejection was diagnosed This dose was tapered in 
3- or 5-dav p e n o d s to 100, 75, 50, 40, 30, and 25 mg Intravenous 
steroid pulses were not used T r e a t m e n t was switched to the 
alternative regimen if there was no improvement of renal func­
tion after 10 days or if a deterioration of renal function occurred 
after completion of the t rea tment course T h e day of reversal 
of a rejection episode was defined as the second of .i consecutive 
days that the serum creatinine decreased 
Peripheral Τ cells were determined with t h e 2-ammo ethyl-
ibothiouromum bromide technique ( 12) Briefly, in t h e Hemalog 
U, lymphocytes were counted in whole blood, and recounted 
after separation with Picoll T h e percentage of rosette-form mg 
cells was then determined, and absolute Τ cell levels were 
calculated from these data T h e RATG level was determined 
with a radial immunodiffusion technique and antibodies to 
RATG with an agglutination assay Complement components 
C3, C4, and factor R were measured by radial immunodiffusion 
For the detection of circulating immune complexes, a modifi­
cation of t h e C l q binding assay described by Zubler et al (13) 
was used For statistical evaluation the following methods were 
used Mann-Whitney i r test, test of Kruskal-Wallis, Wilcoxon 
matched pairs test and χ2 test Differences were considered 
significant if Ρ levels were less than 0 05 
RESULTS 
Table 1 shows that the RATG and prednisone groups were 
similar for factors that might influence graft surv ival T h e mean 
serum creatinine level, measured on the day when the at ute 
rejection was diagnosed, was J fi mg/lOO-ml in the prednisone 
group and 3 6 mg/100 ml in the RATG group, also indicating 
that there were no great differences between both groups in the 
severit> of rejection T h e results obtained with the two treat­
ment protocols are given in Table 2 and Figure 1 
In the RATG group only two patients showed no response at 
all, whereas there were five such patients in the prednisone 
group Resides t h e five immunological failures in the RATG 
group, there was one technical failure This was in a patient 
who developed a leakage from the renal pelvis attr ibutable to 
obstruction after she had responded to t h e RATG treatment 
T h e mean reversal of the rejection occurred 1 1 day earlier in 
the RATG group but this was not significant T h e r e were six 
second rejections in either group t h a t were, according to the 
protocol, treated with t h e alternative regimen T h e mean inter­
val between first and second rejections was 2 2 months longer 
in the RATG group Figure 1 shows that a second rejection 
episode within the first 3 m o n t h s after transplantat ion oc< urred 
onlv once in this group, whereas this was t h e case four t imes in 
t h e prednisone group For the comparison of renal function in 
both groups, we included only patients who had experienced a 
single rejection Serum creatinine levels were not different 
between the two groups T h e 28 patients who never developed 
TABLF 1 Patient data 
Sex male/female 
Age <40/>40 >ears 
Blood group O/non-0 
Blood transfusion 
1 
2 or more 
Unknown 
HLA AB mismatches 
0 
1 
2 or more 
HLA DH mismatches 
0 
1 
¿ 
Unknown 
HLA antibodies 
none 
<50<r 
>50'r 
В cell antibodies 
Negative 
Positive 
Unknown 
Previous transplants none/lor more 
Body temperature at da> of 
«37 >/> 17 2 с 
Interval from transplantation 
tion «; l¿/>l¿davs 
rejection 
to rejec 
RATG 
10/10 
9/11 
8/12 
6 
14 
0 
5 
6 
9 
9 
β 
1 
2 
11 
6 
3 
16 
3 
1 
17/3 
7/13 
10/10 
Prednksoi 
13/7 
13/7 
7/13 
7 
12 
1 
5 
6 
9 
9 
5 
2 
4 
13 
4 
3 
15 
2 
3 
17/3 
7/13 
9/11 
TABLE 2 Response to antirejection treatment and subsequent course 
R A T G 
2 
I 5 
il 2 1 
3 8 
6 
:tion 5 3 
.nths 1 1 
I'lrdnwone 
5 
7 
I •> 
4 9 
6 
1 1 
1 0 
No reversal (no of patients) 
Immunological failures (no of patients)
Mean graft survival of failures (month»)
Mean dav of reversal 
Second rejeclmn episode 
Interval between firs! and second rejecti  
(months) 
Mean serum creatinine level at 6 mo
(mg/100 ml) 
a rejection had a mean serum creatinine level of 1 2 mg/100 ml 
after 6 months, and this was not different from the two treat­
ment groups 
Peripheral Τ cell levels were measured in all pat ients In the 
RATG group we tried to adjust the doses of RATG such that 
the Τ cell levels were between 50 and ISO/mm' At t h e onset of 
rejection, mean Τ cell levels of both t rea tment groups were 
similar (RATG, 870, prednisone, 821/mm 3}, and not signifi­
cantly different from the level of t h e control group of 28 pat ients 
without a rejection ^ Э о / т т ' ) In the RATG group t h e mean 
Τ cell level fell significantly during t reatment, whereas this was 
not the case in the prednisone treated group (Fig 2) 
Since we adjusted the RATG dose to the peripheral Τ cell 
level, it is not surprising that there were great differences in the 
doses between individual pat ients This is shown in Figure 3, 
which also illustrates that reversal of the rejection occurred 
promptly m most cases T h e r e was no relation between cumu­
lative RATG dose and the reversal day Figure 3 also shows 
that the rapidity of t h e reversal provides no information on the 
ult imate outcome of the transplantat ion Two pat ients with a 
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Fif.i HF 1 Graft survival in both 
treatment groups The patients with two 
rejection episodes were treated with ihe 
alternative regimen The vertical broken 
lines indicate the mean onset of First and 
second rejections The numbers between 
these lines refer to the mean intervals 
(months) between first and second rejec 
tions In the prednisone group one pa 
tient died as a result of septicemia after 
abdominal surgerv (+) 
" ' " c e l l s / г п т Э 
( m e a n * S E M ) 
0 0 
6 0 0 
¿.00-
2 0 0 
I l oe fo re re jec t o n 
I ' I d u n n q re j ec t i on I 
X 
ATG p r e d n i s o n e 
FICLRF 2 Mean peripheral Τ cell levels before and during treat 
ment in both groups 
rapid reversal developed renal faüure, whereas in three with 
ver> slow reversals graft outcome was good 
Differences in elimination of RATG might reflect its in vivo 
activit\ and therefore we measured RATG levels in the serum 
There were no differences between RATG levels in the serum 
of pat ients who responded without further rejections (mean 121 
¿tg/ml), in the pat ients who had a second rejection (mean 95 
Mg/ml) and in the t rea tment failures (mean 11 д§/т1) In two 
patients who responded to a single antirejection course RAI G 
levels became zero despite continued administration This was 
also t h e case m one patient of the failure group and in three 
pat ients who later developed a second rejection In only one 
pat ient we were able to detect antibodies against rabbit im­
munoglobulins These antibodies developed 1 week after com­
pletion of t h e RATG course This pat ient ultimately lost her 
kidnev Complement levels were slightly below normal in all 
pat ients that received transplants, but there were no significant 
changes during the rejection t r e a t m e n t Levels of immune 
complexes remained either negative or unchanged in all pa 
t ients 
I he only a d v e n e reactions to the RATG t r e a t m e n t were 
chills and fever which occurred almost exclusively during the 
first infusion 1 wo patients developed slight and transient ar 
thralgias during t h e t rea tment course In none of the pat ients 
did RATG t r e a t m e n t have to be discontinued because of side 
effects 
In the prednisone group there were 29 urinary tract infections 
in 15 pat ients We found significantly less urinary tract infec 
lions in the RATG group (16 in 9 patients) but the incidence 
was high again in the group with no rejection (34 in 19 patients) 
T h e frequencies of all other infections, including cytomegalo 
virus infections were not significantly different T h e r e were 
four cytomegalovirus infections in t h e prednisone group and 
fUe in t h e RA I G group One patient in t h e prednisone group 
died as a result of septicemia 
T h e mean cumulative steroid dose per pat ient after Э m o n t h s 
was 4275 mg in the prednisone group and 3255 mg in t h e RATG 
group Onl\ pat ients who sustained adequate renal function for 
at least 4 month*, were included tn this comparison irrespective 
of whether they had one or two rejection episodes 
DISCUSSION 
T r e a t m e n t of acute rejection with RATG has two obvious 
advantages as compared with a protocol of prophylactic treat­
ment started from the day of t ransplantat ion First, pat ients 
without a clinically apparent rejection do not receive unneces­
sary t reatment with the foreign protein T h a t this is a consid­
erable number of pat ients is illustrated by our finding that 28 
of a total of 68 pat ients h a d no rejection during t h e period of 
s tudy Second if a patient is t reated from the day of transplan­
tation he runs t h e risk of having already formed antibodies 
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cumulat iveATGdose ( m g ) -
FicuHF 3 Relation between cumula­
tive RATG dose and promptness of re­
jection reversal Two patients showed no 
reversal (nght panel) 
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days before reversal n o reversal 
against the rabbit proteins at the time that rejection becomes 
evident, thus making further treatment less effective 
Another problem with ATGs from different sources us their 
variable potency Generally, horse ATG seems to be less effi­
cient than RATG That was the reason we chose the latter 
ATG source Even with ATG of this species, it remains impor 
tant to establish the immunosuppressive activity by performing 
skin graft studies in primates The preparation that we have 
developed compares favorably with ATGs used by other groups 
(ƒ) since it produced a skin graft survival time of 50 days in a 
rhesus monkey and 20 to 30 days in the less sensitive cynom-
olgus model 
Although the results are preliminary and conclusions about 
long-term survival cannot be drawn because of the relatively 
short observation time and the limited number of patients 
treated as yet. several data that are important for clinical 
decision making have already emerged It is clear that reversal 
of acute rejection is possible in most cases by treatment with 
RATG and without raising the dose of steroids This is in 
accordance with the results in two other recent studies, in which 
horse ATG was used as the immunosuppressant drug (в, 9) 
Shield et al (8) only studied rejections in living related donors 
in whom rejections may be generally easier to control because 
of better matching as compared with cadaver donors The 
results of Hardy et al (9) are somewhat difficult to interpret, 
since they started treatment in patients who did not respond to 
3 or 5 days of treatment with high doses of prednisone and graft 
irradiation Although their data are impressive, it cannot be 
completely excluded that in some of their patients the favorable 
result was attributable to a delayed response to the prednisone 
treatment and not to the administration of ATG In our ap­
proach these problems could be obviated by including only 
patients with cadaveric grafts and by studying the efficacy of 
RATG as the sole agent in a prospective randomized trial In 
the RATG group there were more patients who showed reversal 
of their rejection, whereas the time of rejection reversal tended 
to be shorter All but one of the patients with immunological 
graft failure in the RATG group received a subsequent full 
course of prednisone treatment without effect In most of these 
patients a full treatment course with RATG could not be given 
because of leukopenia and thrombocytopenia. In all of the 
failures in the prednisone group, the kidney grafts had to be 
removed before a subsequent RATG course could be given 
The excellent response to RATG in all six patients of the 
prednisone group who developed a second rejection shows that 
second rejection episodes are also responsive to RATG Fur­
thermore, our results indicate that the interval between first 
and second rejection episodes was longer in the RATG group 
As anticipated, the RATG protocol was steroid sparing 
We did not find a correlation between the onset of acute 
rejection and the level of peripheral Τ cells RATG treatment 
caused a large drop in Τ cell levels that occurred in most cases 
immediately after the start of the treatment This drop was not 
seen in the prednisone group (Fig 2) In neither group could 
the Τ cell levels be used to predict the final outcome of the 
treatment procedure 
Bieber et al (14) carried out a study on the clearance rates 
of RATG after a fuU course of RATG had been given to cardiac-
transplant recipients They found that survival was better in 
patients with long RATG half lives Since we did not give a 
continuous course of RATG with a constant dose, we could not 
study the serum half-life, but still some conclusions may be 
drawn from our measurements of RATG levels We found no 
differences in mean RATG levels between failures and success­
ful treatments We even found that in two responsive patients 
levels became zero despite continued administration of RATG 
The same was found in three patients who later on suffered 
from second rejections These findings throw doubt on the 
assumption that measurement of RATG levels might be helpful 
to establish the ideal dose or to predict the outcome of the 
treatment The use of a dose-by-rosette protocol led to great 
differences in RATG doses between individual patients The 
mean dose of RATG and the frequency of its administration 
was lower in the patients with immunological graft failure, but 
this was caused by the fact that three patients in this group 
reacted to the first RATG doses with severe thrombocytopenia 
or leukopenia, which made it necessary to interrupt the treat­
ment We are as yet unable to decide whether the hematological 
changes were merely signs of irreversible rejection or whether 
the rejection occurred because the thrombocytopenia and leu­
kopenia made it impossible to give an adequate treatment with 
RATG It is conceivable that patients who needed only small 
33 
TRANSPLANTATION 
amounts of RATO to keep their Τ cell levels between 50 and 
150/mm might fall in the group of fast responders However 
we found no correlation between the RATG dose and da> of 
reversal (big J) 
I he chills and fever which usually occurred in the first hour 
of the first RATG infusion are most likely caused bv the sudden 
massive cvtolysis of lymphocytes and are not a h>persensitivity 
reaction to the foreign protein as such smce they usually did 
not recur during subsequent infusions 
1 he steroid sparing effect of the RATG treatment will have 
advantages with regard to the many complications in which 
steroids plav a role Long term observations will certainl> give 
information about the incidence of osteonecrosis in both groups 
In this short term study we found only indications for the 
occurrence of less urinary tract infections in the RA FG group 
However we hesitate to draw conclusions from this finding 
sine«, the incidence in the group with no rejection was at least 
as high as in the prednisone group It has been suggested that 
c\tomegalovirus infections occur more frequently after ATG 
but in our study such an increased incidence was not found 
Our results show that t r e a t m e n t with RATG in a dose by 
rosette protocol is an effective and safe method to treat rejec 
tion T h e results are at least as good as those with high oral 
doses of prednisone whereas the RATG protocol is definiteh 
steroid sparing 
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Treatment of Second and Late Renal Allograft Rejection 
With Rabbit Anti-Human Thymocyte Globulin 
A. J. Hoptsma, P. Reekers, J. G. Kreeftenberg, H 
IN HUMAN renal transplantation, anti-thymocyle globulin (ATG) has been used 
for many years. Initially, ATG was adminis­
tered from the day of transplantation in most 
clinical trials, and the results of these trials 
are conflicting. An increasing number of 
recent studies deal with the efficacy of ATG 
when started at the moment of a first rejec­
tion.' " Although treatment protocols differ 
widely, most studies have shown some benefi­
cial effect of this form of treatment. The 
information on the efficacy of ATG treat­
ment, when used for second rejections, late 
rejections (> 3 months after transplantation), 
or steroid-resistant rejections is still scanty.' 
^
1 2
'
3
 Moreover, in all these studies ATG was 
used as an adjunctive agent in combination 
with high doses of steroids so that the effect of 
ATG by itself is difficult to assess We have 
therefore treated second, late, or steroid-resis­
tant rejections with ATG as the sole anti-
rejection agent. 
MATERIALS AND METHODS 
All but one patient received a cadaver kidney Treat­
ment consisted of prednisone and azathiopnne from day 
of transplanlalion When a first rejection occurred within 
3 months after transplantation, the oral prednisone dose 
was raised to 200 mg/day and tapered in periods of 3-5 
days to 25 mg/day in about 3 weeks Anti-rejection 
treatment with RATG consisted of an initial dose of 4 
mg/kg body weight, further doses ranging from 2-7 
mg/kg depending on the peripheral T-cell levels We tried 
to keep these levels between 50 and 150/μΙ '* The predni­
sone dose was not raised during this latter treatment 
RATG was prepared according to the method 
described by Kreeftenberg и Peripheral Τ cells were 
determined with the amino elhyl-isolhiouronium bromide 
(AET) rosetting technique16 and absolute figures were 
estimated with the Hemalog-D R ATG-levels were deter­
mined with a radial immunodifTusion technique and 
antibodies against RATG with an agglutination assay A 
rejection was diagnosed according to standard criteria 
and was proven by a renal biopsy in most cases The day 
of rejection reversal was defined as the second of three 
consecutive days that the serum creatinine decreased 
Twelve patients received RATG infusions for a second 
J. J. van Lier, P. J. A. Capel, and R. A P. Koene 
rejection episode that occurred within 3 months after 
transplantation (early second rejections) Six of these 
patients had experienced a steroid-resistant first rejec­
tion. which was defined as a failure of renal function to 
improve after 10 days of treatment with high doses of 
prednisone, or as a repeated fall of renal function immedi­
ately after completion of a treatment course There were 
15 patients who received RATG treatment for a rejection 
occurring more than 3 months after grafting (late rejec­
tions) Twenty patients treated for their first acute rejec­
tion with RATG served as a control group 
RESULTS 
Early Second Rejections 
The 12 patients who were treated with 
RATG infusions for their second rejection 
episode within the first 3 months after trans­
plantation had all received the conventional 
high doses of prednisone during their first 
rejection episode. The results of the subse­
quent RATG treatment are given in Table I, 
and they show that compared with the 
patients who received RATG for their first 
rejection episode (controls), the response was 
less impressive: reversal occurred more slowly 
and there were more patients in whom renal 
function did not improve. The mean dose of 
RATG was similar in both groups, as was the 
total number of gifts On the other hand mean 
RATG levels and T-cell levels were higher 
during treatment. Administration of RATG 
in the second rejection group often had to be 
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ТаЫ· 1 Response to Anti 
Number of patients 
Mean serum creatinine at day of rejection 
(mg/100 mil 
Mean day of reversal 
No reversal of serum creatinine 
(number of patients) 
Mean dose of RATG (mg) 
Mean number of RATG gifts 
Mean RATG level Ιμβ/hm) 
Mean Τ cells during treatment (per μΙ) 
Mean serum creatinine (mg/100 ml) 
6 months after treatment 
'Patients who received RATG for their first rejection 
fNot calculated because of low number of patients 
{Mean level of 12 patients Three patients had a graft failu 
stopped lemporanly because of thrombocyto­
penia and leukopenia The mean serum cre­
atinine level at 6 months after anti-rejection 
treatment was lower in the control group One 
patient lost his kidney 9 months after trans­
plantation ЛИ other kidneys arc still func­
tioning (follow-up ranging from 5 months to 2 
years) Adverse reactions to RATG were less 
frequent in the second rejection group Only 
half of them showed transient fever during the 
first infusion This occurred in 90% of the 
control patients Other reactions were not 
seen Antibodies against RATG were not 
found in the second rejection group In 10 
patients a renal biopsy was performed before 
the start of the treatment of the second rejec­
tion There were three purely vascular rejec­
tions, six combined vascular and interstitial 
rejections, and one interstitial rejection The 
patient who lost his kidney had a combined 
ι ejection In the subgroup of six patients in 
whom the first rejection had been steroid-
rcsistant, we reversed the rejection with 
RATG in all cases 
Late Rejections 
There were 15 patients in (his group, 8 of 
them had received the conventional high dose 
of prednisone for their first acute rejection 
within 3 months after transplantation The 
remaining seven patients had not experienced 
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Treatment and Subsequent Course 
Second Late 
Refection Re|eclion Control 
( < 3 months) ( > 3 months) Group" 
12 15 20 
29 2 2 36 
4 5 — t 3 8 
4 11 2 
1375 2005 1203 
6 0 83 5 8 
171 196 121 
312 300 190 
16 1 6t 11 
a rejection during the first 3 months The 
mean interval between transplantation and 
rejection was 15 months (range 3-94 
months) The results obtained in this group 
are also given in Table 1 The mean day of 
reversal was difficult to assess, because only 4 
of the 15 patients showed a reversal of their 
serum creatinine Eight patients needed sub­
sequent treatment with high doses of predni­
sone after completion of the RATG course, 
whereas there were only two such patients in 
the group of early second rejections The 
mean RATG dose and the mean number of 
gifts was higher, but despite these higher 
doses we could not sufficiently depress the 
T-cell levels (mean level ЗОО/μΙ) The mean 
RATG level was higher compared with the 
control group Three patients lost their kid­
neys by immunologic failure, which occurred 
at a mean of 3 5 months after treatment In 
the remaining 12 patients, the mean serum 
creatinine at 6 months after treatment was 
higher than in the control group All patients 
underwent a renal biopsy One patient had a 
purely vascular rejection, 10 patients had 
combined rejection, and 4 patients had inter­
stitial rejection All patients who eventually 
lost their kidney had a combined rejection 
Antibodies against RATG were not found 
The side effects of RATG in the late rejection 
group were also less Half of the patients 
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RATG TREATMENT OF REJECTIONS 
Table 2 Incidence of Infections Within Three Months After Treatment 
Number of patients 
Urinary tract infections 
Other infections 
Cytomegalovirus infections 
Prior cytomegalovirus infections 
Second 
Refections 
(^Э months) 
12 
6 
2 
2 
3 
Late 
Rejections 
(>3 months) 
15 
1 
2 
2 
3 
Control 
Group 
20 
29 
8 
5 
— 
suffered from fever during the first infusion 
Also in this group, five patients showed slight 
signs of serum sickness In the control group, 
we found 18 patients with fever and 2 with 
serum sickness In no case did these side 
effects necessitate discontinuation of the 
RATG treatment 
The infection incidence in all groups is 
compared in Table 2 In both the early and 
late rejection group there were fewer urinary 
tract infections and other infections compared 
with the control group If prior infections with 
cytomegalovirus are taken into account, the 
incidence was the same for all groups 
DISCUSSION 
Our results show that RATG treatment of 
second rejections that occur within 3 months 
after transplantation is successful in most 
cases, even if they have been resistant to high 
oral prednisone treatment An exception must 
be made for those steroid-resistant rejections 
that are so severe that the kidney is lost before 
subsequent RATG treatment can be insti­
tuted l 0 " In the few earlier reports about 
treatment of second rejections, ATG was 
always used as an adjunctive agent ' 5 '2 " Our 
finding that the beneficial effect can be 
obtained without raising the prednisone dose 
is especially encouraging It is worthwhile to 
mention that RATG treatment can still be 
effective when it is given some lime after the 
onset of the rejection We have treated two 
patients in whom rejection was unfortunately 
diagnosed 10 days after its onset Despite this 
delay, there was a prompt response to RATG 
treatment and complete reversal was attained 
Both patients now have normal renal function 
at 6 and 25 months after transplantation, 
respectively It is also remarkable that in 
biopsy-proven rejections of predominantly 
vascular type treatment was so successful It 
raises doubt about the generally held opinion 
that vascular rejection is almost always resis­
tant to treatment 
In the late-rejection group, the results were 
rather disappointing In most cases we could 
not induce reversal of the scrum creatinine It 
was striking that in only three patients did the 
rejection go on to complete renal failure In 
the remaining patients, renal function stabi­
lized Probably, RATG treatment halted the 
rejection in some of these patients, but it is 
difficult to assess whether this holds for all 
patients since eight of them received a subse­
quent course with high oral prednisone 
In both treatment groups it was more diffi­
cult to depress the T-cell levels with RATG 
than in the control group In the early second-
rejection group, this was caused mainly by the 
high incidence of leukopenia and thrombocy­
topenia, which prevented us from giving 
RATG more frequently In the late-rejeclion 
group, the patients seemed to be more resis­
tant to RATG treatment, since T-cell levels 
remained relatively high, despite the fact that 
the mean total dose of RATG administered 
was much higher than in the control group 
The reasons for this apparent resistance are 
not clear 
The incidence of infections in both treat­
ment groups was lower than in the control 
group These figures are somewhat difficult to 
interpret, because it can be expected that the 
infection rale will decline late after transplan­
tation and both treatment groups received 
RATG at a later stage than the control group 
Still, the absolute figures are surprisingly low 
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Together with the almost complete absence of 
adverse reactions, this indicates that RATG 
treatment is a relatively harmless procedure. 
We conclude that RATG is not only effec­
tive in reversing first rejections as we have 
shown earlier,10" but that early second rejec­
tions are equally sensitive. For the present this 
latter conclusion must be limited to patients 
who received steroids for their first rejection. 
We have not enough systematic experience in 
patients who received RATG for both their 
first and second rejections, although our pre­
liminary results in a few cases suggest that 
1 Birkeland SA Ada Med Scand 198 489. 1975 
2 Dcodhar SO, Konomi K, NakamoloS, el al Trans­
plant Proc3 758, 1971 
3 Filo RS, Smith EJ, Leapman SB Transplantation 
30 445, 1980 
4 Filo RS, Smith EJ, Leapman SB Transplant Proc 
13 482.1981 
5 Hardy MA, Nowygrod R, El berg Λ, el al Trans­
plantation 29 162, 1980 
6 Howard RJ, Condie RM, Sutherland DER. el al. 
Transplantation 24 419, 1977 
7 Howard RJ. Condie RM, Sutherland DER. et al 
Transplant Proc 13 473, 1981 
8 Mee AD, Evans DB Lancet 2 16, 1970 
RATG is often still effective when given for 
the second time in the same patient. Late 
rejections, on the other hand, showed almost 
no response. In this group of patients, primary 
treatment with prednisone might be a better 
choice. 
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SUMMARY 
The influence of DRw6-antigen on graft survival was studied in a single 
center study in 223 recipients of a cadaveric kidney. Although graft 
survival in 148 DRw6-negative recipients was not significantly diffe-
rent from that in 75 DRw6-positive recipients, the percentage of pa-
tients without a re]ection episode in the first three months after 
grafting was significantly less in the DRw6-negative recipients 
(P=0.03). In DRw6-positive patients who had received RATG as the first 
antire^ection treatment, graft survival was significantly better than 
in predmsone-treated DRw6-positive recipients. In the DRw6-negative 
patients RATG treatment gave also better results, but these differences 
were not significant. When RATG treated patients were excluded from the 
analysis the difference in graft survival between DRw6-negative and 
positive patients became apparent (P=0.03). These findings show that 
the negative influence of the DRw6-antigen present in the recipients is 
counterbalanced by the beneficial effect of RATG treatment for first 
rejection episodes. 
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INTRODUCTION 
Matching for DR-antigens has been reported to improve graft survival in 
renal transplantation1/ . Recently, Hendriks et al showed that the pre-
sence or absence of the DRw6-antigen in the recipient is an even more 
important factor3,'*. DRw6-negative recipients had a significantly bet-
ter one-year graft survival than DRw6-positive patients. They also 
found that HLA-DR matching improved renal allograft survival only in 
the DRw6-positive recipients. In DRw6-negative patients a slightly be-
neficial effect of HLA-DR matching was observed, but this was not sig-
nificant. On initial analysis of graft survival, patient survival, and 
effectiveness of HLA-DR matching in our DRw6-positive and DRw6-negative 
patients, we could not confirm these findings. We have therefore, stu-
died whether differences in treatment protocols for rejection might be 
responsible for our failure to find a negative influence of the DRw6-
antigen on graft survival in DRw6-positive recipients. 
PATIENTS AND METHODS 
In this single center study only patients grafted after January 1, 1978 
were studied, because HLA-DR typing was not performed routinely before 
that time. All cadaveric transplantations of which HLA-DR types of both 
donor and recipient were known, were admitted. All patients had receiv-
ed at least one blood transfusion before transplantation and had been 
followed for at least three months after grafting. 
From the day of transplantation all patients received prednisone in a 
dose of 100 mg daily with tapering in periods of 5 days to 75, 50, 40, 
30, and 25 mg. The azathioprine dose was 1.5 mg/kg body weight when the 
creatinine clearance was less than 25 ml/min and 3 mg/kg at higher 
clearances. The dose was also decreased when the leucocyte count was 
less than 4,000/mm3 or when the thrombocytes were less than 
100,000/mm3. Acute rejections were treated in two different ways, ac-
cording to an earlier described randomization protocol^. In one group 
of patients the oral dose of prednisone was raised to 200 mg/day and 
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tapered xn 3- or 5-day periods to 100, 75, 50, 40, 30, and 25 mg. In­
travenous steroid pulses were not used. In the other group acute reac­
tions were treated with a three-week course of rabbit antithymocyte 
globulin (RATG) , . The initial dose was 4 mg/kg and additional doses 
were between 2 and 7 mg/kg depending on the peripheral Τ cell level 
that we tried to keep between 50 to ISO/mm . The prednisone dose was 
not raised in these patients except for the addition of 50 mg of pred­
nisolone to the first and 25 mg to each following RATG infusion to 
avoid acute side effects. If the patient experienced a second rejection 
episode or if the first rejection responded insufficiently to treat­
ment, the alternative treatment was given. Graft failure was defined as 
a return of the patient to hemodialysis, regardless of whether the 
cause of failure was immunological or non-immunological. Patients who 
died were also counted as graft failures, even if the graft was func­
tioning at the time of death. Patient failures include all patients who 
died even if the cause of death was unrelated to the transplantation. 
Typing for HLA-DR antigens (DR1-DR10, МВ1-МВЭ, MT2-MT3) was done with 
the NIH standard lymphocytotoxicity assay on enriched B-lymphocyte sus­
pensions, obtained by resetting with aminoethyl-isothiouronium bromide 
(AET) coated sheep red blood cells. The antigen DRw6 was serologically 
defined by positive reactions with MB1 and MT2 sera. Recipients were 
all typed in the same laboratory and their HLA types were all confirmed 
by typing of family members. The gene frequencies of the recipient's 
DR-antigens in the whole group and the two treatment groups are given 
in Table I. As a result of the family typing the number of unknown DR-
antigens was kept to a minimum. The HLA type of the kidney donors was 
defined by comparing the results of two independent typing 
laboratories. The frequency of unknown DR-antigens was 0.11 for the 
whole group. If at a given locus one antigen was unknown, the donor was 
considered to be homozygous for this specificity. The HLA-AB match 
grade was calculated as follows: 1 point with 1 mismatch at the 
A-locus, 2 points with 1 mismatch at the B-locus, and 3 points with 2 
or more mismatches. One point was assigned for each DR mismatch. 
The actuarial survival curves were estimated with the survival-program 
of SPSS. The log rank test according to Mantel' was applied to test 
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Table I. Gene frequencies of DR antigens in the recipients 
DR 1 
DR 2 
DR 3 
DR 4 
DR 5 
DR 6 
DR 7 
DR 8 
DR 9 
DR 10 
Blanks 
Total Group 
(n=223) 
0.11 
0.15 
0.13 
0.14 
0.14 
0.17 
0.10 
0.03 
0.00 
0.00 
0.03 
RATG Group 
(n=66 ) 
0.14 
0.09 
0.13 
0.16 
0.13 
0.20 
0.09 
0.03 
-
-
0.04 
Prednisone Group 
(n=77) 
0.06 
0.16 
0.12 
0.10 
0.16 
0.21 
0.15 
0.02 
0.01 
-
0.01 
differences in graft survival at 3, 6, and 12 months after transplanta-
tion. For further statistical evaluations the chi-square test for the 
rxk table (for the 2x2-table with correction for continuity) and the 
Mann-Whitney U-test were used. 
RESULTS 
Two hundred and twenty.-three patients were included m the study. There 
were 148 DRw6-negative recipients and 75 DRw6-positive recipients. Ta-
ble II shows patient data and the main risk factors for graft survival 
in both groups. Significant differences were not found. 
Table II. Patient data 
Male (%) 
Mean age (years) 
Mean match grade DR 
Mean match grade HLA-AB 
First transplantation (%) 
Mean number of blood transfusions 
Mean dialysis period (months) 
DRw6-negative 
patients 
(n=148) 
55 
35 
0.80 
2.1 
80.5 
4 
24 
DRw6-positive 
patients 
(n=75) 
55 
35 
0.75 
2.2 
85.4 
6 
26 
45 
% graft survival 
100 
4 0 
2 0 
- 1 — 
3 
D R W 6- negative (n =148) 
•o о 86 
¿.¿, 
-· DRw 6-posi t ive (n=75) 
—ι 1 1 
6 9 12 
m o n t h s after transplantation 
Fig. 1 Actuarial survival curves of cadaveric renal allografts in 
DRw6-positive and DRw6-negative recipients. Numbers of patients 
at risk are given on the curves (N.S. = not significant) 
Actuarial survival curves for both groups did not differ significantly 
(Fig. 1). Graft survival at three months was 79% for the DRw6-negative 
recipients and 76% for the positive patients. Neither m the DRw6-nega-
tive nor in the DRw6-positive patients was a beneficial effect of 
HLA-DR matching found. Significant differences in patient survival be­
tween both groups were also not found. Patient survival after three 
months was 94% both for the DRw6-negative and positive patients. De­
tailed analysis of the post-transplant course in both patient groups 
failed to show significant differences for all but one variable (Table 
III). The percentage of patients without a rejection in the first three 
months after transplantation was significantly higher in the DRw6-nega-
tive recipients (41.2% vs. 25.3%; P=0.03 ). We, therefore, analyzed 
whether the form of treatment given for these rejections had influenced 
graft survival. Patients without a rejection in the first three months 
were excluded from this analysis. In the DRw6-positive group a highly 
significant influence was observed. When the first rejection had been 
treated with prednisone, graft survival after three months was 61%, 
while graft survival for the RATG treated patients was 88% (Fig.2; 
P=0.003). In the DRw6-negative patients graft survivals after three 
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Table III. Patient course in the first three months after 
transplantation 
DRw6-negative 
patients 
(n=148) 
DRw6-positive 
patients 
(n=75) 
Acute tubular necrosis (%) 43 
Rejection free interval (days) 19.7 
Urinary tract infections 
(mean per patient) 1.4 
Respiratory tract infections 
(mean per patient) 0.3 
Cytomegalovirus infections (%) 20 
Herpes infections (%) 9 
Mean prednisone dose (mg) 3400 
Mean serum creatinine (ymol/) 106 
Patients without rejection (%) 41.2 
43 
20.1 
1.5 
0. 
25 
11 
3500 
115 
25. 3* 
0.03. All other differences were not significant 
% graft survival 
100 
2 0 
RATG(n=25) 
15 
13 
prednisone (n = 31 ) 
overall p=0 003 
-ι 1 1 ' 
6 9 12 
months after transplantation 
Fig. 2 Actuarial survival curves of cadaveric renal allografts in 
DRw6-positive recipients in relation to treatment for acute 
rejection. Patients without rejection in the first three months 
were excluded from the analysis 
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% graft surv ival 
100 
4 0 
2 0 
RATG ( η = 41 ) 
prednisone ( η = 46 ) 
1 1 1 1 
3 6 9 12 
months after transplantation 
Fig. 3 Actuarial survival curves of cadaveric renal allografts in 
DRw6-negative recipients m relation to treatment for acute re­
jection (N.S. = not significant). Patients without rejection in 
the first three months were excluded from the analysis 
months for patients treated with prednisone or RATG were 67% and 78% 
respectively (Fig.3), a difference that is not significant. In an at­
tempt to obtain information on a group of patients, that resembled the 
patients studied by Hendriks et al^ as closely as possible, we carried 
out an overall analysis of the whole group, including both patients 
with and without rejections in the first three months, but omitting all 
patients that had received RATG. A summary of all patient groups stu­
died is given in Table IV. In this analysis a significant difference in 
graft survival between DRw6-negative and DRw6-positive recipients be-
Table IV. Summary of patient groups 
DRw6 + DRw6 
1. T o t a l g roup ( F i g . 1 ) 75 
2 . RATG g r o u p 25-
3. Prednisone group 31-
4. Patients without rejection 19 
5. Total of groups 3 and 4 (Fig. 4) 50 
(Fig.2) 
148 
41 
46-
61 
107 
(Fig.3) 
48 
% graft survival 
100 
ДО 
2 0 
Ί 
D R W 6- negative ( η =107) 
2 9 
D R W 6 positive ( n = 50) 
overall p=0 03 
3 6 9 12 
months after transplantation 
Fig. 4 Actuarial survival curves of cadaveric renal allografts in 
DRw6-positive and DRw6-negative recipients with exclusion of 
patients who received RATG as a treatment for their first re­
jection 
came apparent (Fig. 4, P=0.03). Also in this subgroup we found no sig­
nificant influence of DR matching on graft survival, neither in the 
whole group nor in the DRw6-positive and negative groups separately. 
Also when donor-patient combinations in which only one HLA-DR specifi­
city of the donor was known were omitted from this latter analysis, a 
significant influence of DR matching was absent in either group. In all 
analyzed subgroups, patients who had received a kidney with one DR mis­
match performed slightly better than DR matched combinations. 
DISCUSSION 
The higher percentage of rejections in the recipients who carried the 
DRw6-antigen suggested that these patients had an increased immune res­
ponsiveness to the graft. This is in accordance with the data of other 
groups3,4,8. However, in contradistinction to these reports this higher 
incidence of rejections was not reflected in a decreased graft survi­
val . We supposed that this might be related to the fact that a large 
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group of our patients had received RATG as an antirejection treatment. 
Since April 1979 we had carried out a randomized trial in which pa­
tients who developed an acute rejection of their graft were treated 
with either RATG or high oral doses of prednisone5,6. A second rejec­
tion was treated with the alternative protocol. The results of this 
trial demonstrated that the treatment chosen for the first rejection 
episode was of importance. Patients who received RATG as the first 
treatment had a significantly better graft survival than those who re­
ceived initial prednisone treatment (in preparation). Our current ana­
lysis shows that this beneficial effect of RATG was especially appa­
rent in the DRw6 positive group, where graft survival after RATG was 
88% at 3 months and 80% at one year. Graft survival rate in predmsone-
treated DRw6 positive patients was significantly worse (61% and 42% at 
3 and 12 months respectively). If patients who received RATG for their 
first rejection were eliminated from the overall analysis, a signifi­
cant difference of graft survival between DRw6 positive and negative 
recipients became detectable. These results suggest that treatment with 
RATG for first rejection episodes had obscured the deleterious effect 
of the presence of DRw6 in the recipients. A recent report" m which 
administration of antιlymphocyte globulin did not improve the survival 
in DRw6 positive recipients, seems to contradict oar findings. However, 
the study comprised only six DRw6-positive patients, who received the 
antilymphocyte globulin. Furthermore, the preparation used was from a 
different source and was given as a continuous treatment from the day 
of transplantation, whereas in our study RATG was started only after 
the diagnosis of rejection had been made. These differences might ex­
plain the failure of others to find a beneficial effect of antilympho­
cyte globulin in DRw6-positive recipients. 
We observed no influence of DR matching on graft survival rate in our 
patients, neither for the whole group nor for the DRw6-positive or 
DRw6-negative recipients. Such an influence was also absent when pa­
tients who received RATG-treatment were omitted from the analysis. We 
actually found in all analyses that patients who received a 1-DR-mis-
matched graft consistently showed a better graft survival than patients 
with a DR-matched or a 2-DR mismatched graft. The differences were, 
however, not significant. In this regard we could not confirm the fin-
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dings of Hendriks et al who found that matching for DR antigens is of 
great importance in DRw6-positive recipients. There is, however,another 
study in which an influence of DR-matching in these patients is also 
absent"· More data are obviously required to settle this point. 
Our results suggest that, especially in DRw6-positive recipients, first 
rejections should be treated with antithymocyte globulin rather than 
with high doses of prednisone. 
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CHAPTER б 
IMPROVED PATIENT AND GRAFT SURVIVAL AFTER TREATMENT OF ACUTE REJECTIONS 
OF CADAVERIC RENAL ALLOGRAFTS WITH RABBIT ANTITHYMOCYTE GLOBULIN 
Andries J Hoitsma, Henk JJ van Lier, Paul Reekers, and Robert AP Koene 
ABSTRACT 
In a prospective randomized trial, we compared the effectiveness of 
rabbit antithymocyte globulin (RATG) in the treatment of acute renal 
allograft rejection with the results of treatment by high oral doses of 
prednisone. Fifty recipients of cadaveric kidneys were included in each 
group. In the RATG group, the prednisone dose was not increased and a 
dose-by-rosette protocol was used to keep Τ cell levels between 50 and 
ISO/mm-^. The three months and one year graft survival rates in the 
RATG group were 84% and 78%, and were significantly higher than those 
in the Prednisone group (64% and 50%). A significant difference in pa­
tient survival could also be detected. In the RATG group the three 
months and one year patient survival rates were 100% and 98% , while 
patient survival rates in the Prednisone group were 91% and 84% respec­
tively. The percentage of second rejections was higher in the Predni­
sone group and 70% of these patients showed a good response to subse­
quent RATG treatment. Renal function after six months was similar in 
both groups. No serious side effects were encountered in the RATG 
group. The incidence of infections was the same in both groups. Treat­
ment of acute rejections with RATG is preferable to prednisone treat­
ment. It improves long term graft and patient survival and is steroid 
sparing. 
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INTRODUCTION 
Although heterologous antilymphoid globulin (ALG) has proven to be a 
highly effective immunosuppressive agent in animal experiments the 
question of whether treatment with ALG improves renal graft survival in 
man is still a matter of debate. Reports on the prophylactic use of ALG 
during the first weeks after transplantation are contradictory. In re-
cent years several studies have appeared that suggest a greater effica-
cy of ALG when used not prophylactically, but as an agent to treat al-
ready established rejections^-'·'. Tnterpretation of the results of 
these studies is hampered by the fact that in many protocols ALG was 
used as an adjunct to treatment with high doses of steroids^" , ' . 
Until now only two controlled studies have been published in which ALG 
was the sole drug to treat a rejection crisis, and in both a good res-
ponse was demonstrated^, . Again, the results are difficult to inter-
pret because one study concerned only transplants from living related 
donors6, and in the other the procotol included also prophylactic 
treatment with ALG . We have previously reported on our preliminary 
results of a randomized controlled trial in which rabbit antithymocyte 
globulin (RATG), used as the sole treatment in acute rejection of cada-
veric renal grafts, was compared with prednisone treatment^'. The pre-
sent report deals with the final outcome of this trial. 
PATIENTS AND METHODS 
Only patients with first rejection episodes within three months after 
transplantation were admitted to the protocol. Related donors, diabetic 
patients, and patients who had received a RATG course earlier were ex-
cluded. The prospective trial included patients transplanted between 
February 1979 and December 1982. The trial ended in July 1983, when all 
patients had been followed for at least six months after transplanta-
tion. During the period of the trial 227 transplantations were carried 
out in our hospital. Included in our trial were 100 recipients of a ca-
daveric renal allograft of which 50 received high oral doses of predni-
sone and 50 were treated with RATG for their first acute rejection. 
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Sixty-six patients who did not experience a rejection in the first 
three months after transplantation served as a control group. Sixty-one 
recipients were excluded for the reasons given in Figure 1· The RATG we 
used was prepared according to the method of Kreeftenberg^ . Patients 
were allocated to the different treatment groups initially according to 
the minimization method of Taves^ , later on according to the standar­
dized variance method'°,''»while balancing for the following risk fac­
tors: sex, age, blood group of the recipient, number of blood transfu­
sions, number of mismatches for HLA-A, B, and DR antigens, presence of 
lymphocytotoxic antibodies and В cell antibodies, number of previous 
transplants, and time of onset of the acute rejection after transplan­
tation. The treatment protocol has been described earlier'^. Briefly, 
until the diagnosis of acute rejection was made all patients were 
treated similarly with prednisone and azathioprme. In the RATG group 
the acute rejection was treated with a three-week course of RATG intra­
venously. The initial dose was 4 mg/kg and further doses ranged from 
2-7 mg/kg depending on the peripheral T-cell level, which we tried to 
227 Patients 
61 Exclusions 
166 Trial Patients 
9 Nonfunctioning kidneys 
14 Diabetic patients 
— 17 Related grafts 
21 Earlier RATG course or 
refusal to participate 
ι— 66 Patients without 
rejection 
50 RATG treated patients 
— 50 Prednisone treated 
patients 
Fig. 1 All patients transplanted between February 1979 and December 
1982 and the distribution in trial patients and exclusions 
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keep between 50-150 mm/J . The prednisone dose was not raised in this 
group. In the Prednisone group the oral dose of prednisone was raised 
to 200 mg/day and tapered in about two weeks to 25 mg. The alternative 
regimen was chosen if there was no improvement of renal function within 
10 days. Second rejections were also treated with the alternative pro­
tocol. The day of reversal of an acute rejection was defined as the se­
cond of three consecutive days that the serum creatinine had decreas­
ed. The match grade for A-, B-antigens was calculated as follows: 1 
point with 1 mismatch on the A-locus, 2 points with one mismatch on the 
B-locus, and 3 points with 2 or more mismatches. For the calculation of 
the DR-match grade one point was assigned for each DR-mismatch. Peri­
pheral Τ cells were determined with the amino-ethylisothiouromum bro­
mide (AET) rosetting technique^". Thrice weekly, RATG levels were de­
termined with a radial immunodiffusion technique and antibodies to RATG 
with an agglutination assay. Antibodies to cytomegalovirus (CMV) were 
determined with an indirect enzyme-linked immunosorbent assay. Patients 
were considered to have had a prior CMV infection when the antibody 
titre, was higher than 1:2 and were considered to have a current CMV 
infection when clinical signs of CMV infection were accompanied by a 
fourfold increase in antibody titre. Graft failure was defined as a re­
turn of the patient to haemodialysis, regardless of whether the cause 
of failure was immunological or non-immunological. Patients who died, 
were also counted as graft failures, even if the graft was functioning 
at the time of death. Patient failures include all patients who died 
even if the cause of death was unrelated to the transplantation. For 
statistical evaluation the following methods were used: Mann-Whitney U 
test, test of Kruskal-Wallis, the Wilcoxon matched-pairs test, chi-
square test. Survival at 3, 6, and 12 months were evaluated with the 
log rank test according to Mantel2". Survival rates were estimated with 
the survival procedure of the SPSS package. Differences were considered 
significant if Ρ levels were less than 0.05. 
RESULTS 
Factors that might influence graft survival were similar in the RATG 
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and Prednisone group as shown in Table I. No significant differences 
could be detected. In Fig. 2 the graft and patient survival curves of 
all 166 patients are shovm. The one year graft and patient survival 
were 76% and 96% respectively. The actuarial graft survival curves for 
both treatment groups are shown in Fig. 3. A significant difference in 
favour of the RATG treated patients was found (P=0.002). The three 
months graft survival was 84% and 64% in respectively RATG and predni-
sone treated patients. Included in the RATG graft failures is one pa-
tient who lost her kidney due to a technical failure. A significant 
difference in patient survival could also be detected (Fig. 4, 
P=0.02). The three months patient survival was 100% and 91% respective-
ly in the RATG and prednisone treated patients. Details of the response 
to antirejection treatment in the two groups are shown in Table II. The 
results suggest that patients treated with RATG fared better with 
regard to nearly each variable, but none of the differences reached the 
level of significance. The number of patients in whom graft failure oc-
curred so fast that a second antirejection treatment could not be given 
was four times higher in the Prednisone group (12 vs 3 patients, 
Years after transplantalion 
Fig. 2 Actuarial patient and graft survival curves of all 166 patients 
included in the trial 
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Table I. Comparison of possible risk factors 
RATG 
(n=50) 
Prednisone 
(n=50) 
Sex: male/female 
Mean age (years) ± S.D. 
Blood group: O/non 0 
Blood transfusions: one/two or more 
Mean match grade 
AB-antigens 
DR-antigens 
DRw6-positive/negative 
HLA antibodies 
none 
•S 50% 
> 50% 
27/23 
35.5 ± 
20/30 
19/31 
2.1 
0.7 
12.3 
28/22 
33.9 ± 12.θ 
14/36 
26/24 
2.2 
0.7 
20/30 
31 
В 
11 
19/31 
28 
11 
11 
В cell antibodies 
negative 
positive 
unknown 
38 
9 
3 
38 
7 
5 
Percentage of first transplantations 
Interval from transplantation to 
rejection: <12/>12 days 
88 
23/27 
86 
24/26 
S.D. = Standard Deviation 
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Fig. 3 Actuarial graft survival curves of the HATG group and the 
Prednisone group 
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Fig. 4 Actuarial patient survival curves of the RATG group and 
the Prednisone group 
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P=0.02). In 20 patients of the Prednisone group a subsequent RATG 
treatment was given within three months either because of resistance to 
the first treatment or for a second rejection. Seventy percent of the 
patients responded to this treatment. Similarly, 17 patients in the 
RATG group received a subsequent prednisone treatment and 65% of the 
patients responded. 
Table II. Response to antirejection treatment 
RATG Prednisone 
No reversal (number of patients) 7 15 
Mean day of reversal 3.5 4.0 
Second rejection episode (%)* 56.3 71.1 
Interval between first and second 
rejection (days) 78 67 
Mean survival of failed grafts 
(months) 11.0 6.3 
Mean survival of patient failures 
(months) 19.9 6.1 
* Percentage of patients at risk 
Peripheral Τ cell levels were measured in all patients. At the onset of 
rejection, mean Τ cell levels of both treatment groups were similar 
(RATG, 1000 +_ 507; prednisone, 1067 +_ 592/mm3), and not significantly 
different from the level of the control group of 66 patients without a 
rejection (951 +_ 408/mm?) · In the RATG group the mean Τ cell level fell 
significantly during treatment (251 +_ 200/mm3) whereas this was not the 
case in the prednisone-treated group (964 + 920/mm-*). The mean total 
RATG dose administered during 3 weeks was 1563 +_ 599 mg and the mean 
frequency of RATG gifts was 7.6 +_ 2.5. Differences in elimination rate 
of RATG might reflect its in vivo activity and therefore we measured 
RATG levels in the serum. There were no differences between RATG levels 
in the serum of patients who responded without further rejections (mean 
= 133 +_ 60 ng/ml), and in the patients who had a second rejection with­
in three months after transplantation (mean » 145 + 61 ng/ml). In only 
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one patient were we able to detect antibodies against rabbit immunoglo-
bulins. These antibodies developed 1 week after completion of the RATE 
course and this patient ultimately lost her kidney. Eight patients re-
ceived a second course of RATG when they developed a third or fourth 
rejection. This course was given 3 weeks to 9 months (mean 4 months) 
after the first RATG course. All patients showed a good response and no 
serious side effects were encountered. 
In Table III the side effects of the RATG treatment are listed. The 
most frequent adverse reactions were chills and fever which occurred 
almost exclusively during the first infusion. In none of the patients 
had RATG treatment to be discontinued because of side effects. The most 
serious problems were encountered in patients with pre-existing overhy-
dration. These patients developed dyspnea with bronchoconstnction du-
ring the first infusion. We now treat these patients with RATG dissolv-
ed in maximally 100 ml of saline instead of the usual 500 ml and this 
has eliminated these reactions. The infection rates in both treatment 
groups and in the control group are shown in Table IV. No significant 
differences could be detected except for the number of cytomegalovirus 
infections, that was significantly lower in the control group, compared 
with both the RATG and Prednisone group. Percentages of patients with 
CMV antibodies prior to transplantation were similar m both groups. 
The follow-up data are listed in Table V. The only significant diffe-
rence between the RATG and prednisone treated patients was in the mean 
cumulative steroid dose within three months after transplantation. In 
the control patients we found a significantly lower serum creatinine, 
both at three months and at the end of the trial (July 1, 1983). Osteo-
Table III. Side effects of RATG treatment 
Chills 31/50 
Fever 31/50 
Arthralgia 5/50 
Bronchoconstnction 5/50 
Nausea 5/50 
Back Pain 4/50 
Thrombophlebitis 2/50 
Urticaria 1/50 
Table IV. Infections xn the first three months after transplantation* 
RATG Prednisone Control 
Urinary tract infections 1.2 i 1-7 1.5 +1.7 1.1 i 1·1 
Respiratory infections 0.40 +_ 0.69 0.32 +_ 0.62 0.18 +_ 0.46 
Cytomegalovirus infection 0.32 +_ 0.47 0.30 +_ 0.46 0.10 + 0.30+ 
* Means + standard deviation 
+
 Significantly different (P=0.009) 
necrosis was four times more frequent in the Prednisone group compared 
to the RATG group or the control group, but this was not significant. 
DISCUSSION 
The preliminary results of our trial already showed that acute rejec-
tion episodes of cadaveric kidney grafts can be reversed by treatment 
with rabbit antithymocyte globulin. Analysis of the results at comple-
tion of the trial now demonstrate that this is reflected in signifi-
cantly better patient and graft survival rates than in patients in whom 
acute rejections are treated with high doses of prednisone. This was 
accomplished with lower overall doses of prednisone and without the 
occurrence of serious complications. 
The design of the trial was such that patients with second rejections 
received the alternative treatment protocol. Thus, in 20 patients of 
the Prednisone group RATG was given for a second rejection and 70% 
showed a good response. However, this favourable effect did not annihi-
late the difference in graft survival between both treatment groups. 
This is obviously caused by the fact that in a significantly larger 
number of patients in the Prednisone group graft failure during the 
first rejection episode occurred so fast that the alternative treatment 
could not be given. Our results, therefore, lead to the conclusion that 
RATG is especially more effective than prednisone in the treatment of 
first rejections. A graft survival after three months of 64% in the 
Prednisone group may seem excessively low, but one should realize that 
this figure only concerns patients with acute rejections in the first 
63 
Table V. Follow-up data 
RATG Prednisone Control 
Mean serum creatinine level 
(pmol/l) 
at 3 months 
at end of trial 
113 
138 
+ 38 
+ 90 
127 
134 
± 72 
+ 126 
93 +_ 25* 
108 + 30 + 
Mean number of antihypertensive 
drugs (per patient) 
at 3 months 0.50 _+ 0.76 
at end of trial 1.09 + 1.16 
0. 76 + 1.05 
1.19 + 1.21 
0.46 +_ 0.87 
1.00 + 1.25 
Mean proteinuria (g/24 hr) 
at 3 months 
at end of trial 
Osteonecrosis (number of 
patients) 
0.6 
0.9 
+ 2.1 
± 1·4 
1 
0.3 
1.S 
+ 0.8 
+ 3.9 
4 
0.5 
0.8 
+ 1.6 
+ 2.6 
1 
Mean cumulative steroid dose 
after three months (mg) 3329 + 681 4250 + 519* 2978 + Μ6Ί 
+
 Ρ < 0.05 (Control vs both treatment groups) 
* Ρ < 0.05 (RATG vs Prednisone group) 
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three months after transplantation. If patients without reaction (38% 
of the whole group) are included in the survival calculations to give 
an overall impression of the results patient and graft survival rates 
are much higher (Fig.2). One year graft survival of the whole group was 
76%, whereas patient survival was 96%. On the other hand, these figures 
may give a somewhat optimistic impression of our overall results, be­
cause 9 patients with primary non-functioning kidneys after transplan­
tation were automatically excluded from our trial since we wanted to 
study the treatment of rejection. If these patients are also included 
in the calculations of the overall data, one year graft survival of the 
whole group becomes 73%, whereas patient survival remains the same, 
96%. 
The use of RATG only when rejection occurs has an important advantage 
over prophylactic treatment, since the considerable number of patients 
who do not develop a rejection are not unnecessarily treated with this 
agent. We adjusted the RATG dose to the peripheral Τ cell level and the 
mean frequency of the gifts was 7.6 times. The value of monitoring Τ 
cell levels is still an open question, but it enabled us to demonstrate 
that results can be obtained with much lower doses, than administered 
in fixed dose regimens where the frequency of administration may be as 
high as 21 gifts 3, 5, 7, 8, 1 0, 1 2, 1 3. Another matter of debate is how long 
ATG must be administered. Three studies report about 10 days treat­
ment 5, 1 2, 1 3, two about a two week course6,8, and three about a three 
week course 3, 7, 1 0. Only Nowygrod et al 9 reported on a comparison be­
tween courses of 10 and 21 days duration. They found that survival ra­
tes were the same, but that in the 10 day course the number of second 
rejections was higher. This point needs further study, but it suggests 
that courses shorter than three weeks are worthwhile trying. 
Several adverse reactions were seen during RATG treatment but most 
were mild. More than half of the patients had chills and fever, which 
occurred almost exclusively during the first infusion. Although we 
could not detect antibodies to RATG (except in one patient) a few pa­
tients had symptoms suggestive of serum sickness (arthralgia and urti­
caria) . In no case had we to stop the RATG treatment course because 
of side effects. We administered second RATG treatment courses to θ pa-
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tients and all of these patients tolerated the treatment very well. 
We found four times more osteonecrosis in the Prednisone group than in 
the RATG group, and this is probably a result of the significantly 
higher steroid dose in the first three months after transplantation. 
This difference is however somewhat hard to evaluate because the inci-
dence of osteonecrosis decreased over the last years, probably due to 
better haemodialysis techniques and the administration of active vita-
min D drugs, and due to lower overall doses of steroids m the Predni-
sone group, because second rejections were always treated with RATG in 
this group. 
It should be noted that our conclusions only apply to rabbit-ATG, be-
cause there may be great differences between ATG-preparations of diffe-
rent species not only with regard to immunosuppressive activity, but 
also concerning side effects and formation of antibodies against the 
foreign protein. We have chosen a rabbit-ATG because there is evidence 
that this is more immunosuppressive than equine-ATG^ . 
In the last few years most attention in renal transplantation has been 
focused on Cyclosporin as a new and potent immunosuppressive agent and 
this tends to obscure the favourable effects that can be obtained with 
older immunosuppressive drugs. A word of caution seems to be justified 
here especially because of the uncertainty with regard to the nephroto-
xicity of Cyclosporin after prolonged use. The one year survival rate 
in the patients who received ATG for their first rejection compares fa-
vourably with the results reported in the recent update of the European 
Multi-Centre Cyclosporin trial"''*, despite the fact that our group com-
prised only patients at increased risk, because patients with no rejec-
tion in the first three months were excluded. The results obtained in 
the Prednisone group in our trial are almost the same as the 1 year 
graft survival figure in the European control group (52%). Our data 
suggest therefore that treatment of acute rejections with RATG is a 
good alternative for Cyclosporin. Apart from lacking the untoward side 
effects of Cyclosporin it is also a less expensive treatment. It re-
mains to be determined whether treatment with Cyclosporin combined with 
RATG for acute rejections can improve the results any further. 
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CHAPTER 7 
GENERAL DISCUSSION 
GENERAL DISCUSSION 
Antilymphocyte serum (ALS) is without any doubt immunosuppressive in 
man. Proof for this has been derived from studies in human volunteers, 
who have been treated with ALS alone. During treatment delayed hyper-
sensitivity was suppressed and the survival of skin grafts from random 
donors was prolonged1,2. ALS has also been shown to prolong the survi-
val of skin allografts used to cover excised third degree burns resul-
ting in improved patient survival^. However, the efficacy of ALS in or-
gan transplantation is still not firmly established. This applies more 
to the adjunctive use of ALS from the day of transplantation than to 
the antirejection treatment with ALS. An overview of the littérature of 
adjunctive therapy and antirejection treatment in human renal trans-
plantation and the place of our investigation in this field is given 
below. For the compilation of this data we have used the original pu-
blications, and comments made in several overview articles « In ad-
dition, data about toxicity of ALS and the new developments regarding 
the use of monoclonal antibodies are given. 
I. Prophylactic treatment with ALS 
In Table I the centers are listed that have used ALS as an adjunctive, 
prophylactic treatment. Many articles report on the same patients. To 
avoid duplications we have listed the papers according to center and 
have combined those dealing with the same patients. An exception has 
been made if centers report about ALS treatment in patients who also 
participated in ALS multicenter trials 8 5, 9 1, 1 0 9, 1 0 9, or if an article 
deals with the combined data of several centers105. The centers are ar-
ranged chronologically according to the first year of the ALS study. If 
a center has carried out several different ALS studies, these are lis-
ted on several places in Table I with different years. If more than one 
center has started its ALS study in a particular year, an alphabetical 
order is followed. 
The first clinical trial of ALS in human renal transplantation was done 
by Starzl and co-workers in 1966^^, and since then more than 50 centers 
have reported on their results. The problems with the initial studies 
of ALS as adjunctive immunosuppressant were many. Usually there is a 
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Table I Prophylactic use of ALS in renal transplantation 
Center 
Year 
of No.of Duration of Specifications Refe-
Start Pat. Treatment of Study rences Final Outcome 
Denver 
Lyon 
Basel 
Boston (PBBH) 
Cleveland 
Rochester 
Salt Lake City 
Auckland 
Birmingham (USA) 
Boston (MGH) 
Cincinnati 
Johannesburg 
Louvain 
Minneapolis 
P a n s 
Sydney 
Zürich 
1966 
1966 
1967 
1967 
1967 
1967 
1967 
1968 
1968 
1968 
1968 
1968 
1968 
1968 
1968 
1968 
214 
177 
29 
58 
53 
36 
8 
10 
50 
60 
50 
19 
Î 
+284 
31 
124 
4 months 
6 months 
3 months 
variable 
4 months 
3 weeks 
variable 
variable 
4 weeks 
variable 
variable 
4 weeks 
variable 
2-3 weeks 
variable 
variable 
Ca/R 
Ca/R 
Ca 
Ca/R 
Ca/R 
Ca/R 
Ca/R 
Ca 
Ca/R 
Ca/R 
Ca/R 
Ca 
7 
Ca/R 
Ca/R 
Ca 
-
-
-
С 
-
-
-
-
_ 
-
С 
_ 
7 
-
С 
С 
1968 51 weeks Ca 
26-33 
34-39 
40 
4 1 , 4 2 
4 3 , 4 4 
4 5 , 4 6 
47 
48 
4 9 , 5 0 
1,51 
5 2 , 5 3 
5 4 , 5 5 
56 
57-63 
64 
65-69 
70 
Boston (BUH) 
Michigan 
1969 
1969 
39 
+ 124 
5 times 
variable 
Ca 
Ca/R 
-
С 
-
-
71-74 
75,76 
Improved graft survival 
Less acute rejections 
No effect 
Less acute rejections 
No effect 
Less severe rejections 
Less acute rejection, 
less steroids 
Less acute rejections, 
less steroids 
No conclusions 
No effect 
Spleen ALS better than 
thymocyte ALS 
Less acute rejections 
No effect 
Better graft survival, 
less rejections, less 
steroids 
No effect 
Better graft sunval, 
less rejections 
Graft survival at 1 year 
= 76% 
Less acute rejections 
No effect 
Table I (continued) 
Center 
Brussels 
Gothenburg 
Multicenter USA 
Stockholm 
Birmingham (UK) 
Multicenter Can. 
Halifax 
Los Angeles (LACU) 
Philadelphia (JMC) 
Toronto (TGH) 
Richmond 
Zürich 
Boston (MGH) 
Multicenter USA 
New York 
Stockholm 
Multicenter UK 
Oslo 
Rennes 
Richmond 
Year 
of 
Start 
1970 
1970 
1971 
1971 
1972 
1972 
1972 
1972 
1972 
1972 
1972 
1972 
1973 
1973 
JM973 
1973 
1974 
1974 
+ 1974 
1974 
No. of 
Pat. 
87 
30 
20 
144 
43 
87 
20 
26 
38 
19 
35 
93 
60 
183 
+ 100 
103 
86 
20 
21 
71 
Duration of 
Treatment 
var lable 
variable 
16 
3 
10 
10 
10 
2 
2 
2-4 
7 
4 
weeks 
weeks 
days 
days 
days 
weeks 
weeks 
weeks 
weeks 
variable 
2 
21 
3 
10 
4 
4 
5 
weeks 
doses 
weeks 
days 
months 
months 
days 
Specif ications 
of Study 
Ca 
Ca 
Ca 
Ca/R 
Ca 
Ca 
Ca 
Ca/R 
Ca 
Ca/R 
Ca 
Ca 
Ca 
Ca/R 
Ca/R 
Ca 
Ca/R 
Ca 
Ca 
Ca 
-
-
С 
-
С 
С 
с 
с 
-
с 
-
-
с 
С 
с 
с 
с 
с 
с 
с 
-
-
MC 
-
-
мс 
-
-
-
-
-
-
-
MC 
— 
-
MC 
-
— 
Refe­
rences 
77 
78,79 
80 
81,82 
83 
84 
85 
86 
87 
88 
89 
90 
2,91 
92 
93-95 
96,97 
98 
99,100 
101 
89,102 
Final Outcome 
Comparison of different 
ALS-batches 
No effect 
Longer ALS treatment 
gives better results 
No conclusions 
No effect 
Less acute rejections 
Favourable effect 
No effect 
Less acute rejections 
Less acute rejections 
No effect 
No improvement 
Improved graft survival, 
less early rejections 
No effect 
Improved graft survival, 
less rejections 
No effect 
No effect 
No effect 
Improved graft survival, 
less rejections, less 
steroids 
High potency ALS improves 
graft survival 
Table I (continued) 
Center 
Year 
of 
Start 
No.of Duration of Specifications Refe-
Pat. Treatment of Study rences Final Outcome 
Birmingham (USA) +1975 26 
Philadelphia(AEMC) jH975 35 
Boston (all cent.) 1976 
Los Angeles (CHLA) 1976 
Richmond jH976 
Pans 1977 
Portland 
Cleveland 
Montreal 
Oslo/Stockholm 
Toronto (TWH) 
Stockholm 
1977 
1978 
120 
28 
40 
24 
35 
31 
1978 40 
1978 30 
1979 21 
1980 23 
4 weeks 
2-4 weeks 
21 doses 
2-4 weeks 
? 
2-4 weeks 
weeks 
weeks 
2-4 weeks 
3 weeks 
3 weeks 
2 weeks 
Ca 
Ca/R 
Ca 
Ca 
Ca 
Ca 
Ca 
Ca 
Ca 
Ca 
Ca 
Ca 
С 
С 
MC 
103 Improved graft survival 
104 Improved graft survival, 
less rejections 
105 Improved graft survival 
106 No effect 
107 Improved graft survival 
108,109 Improved graft survival, 
less steroids 
110 Less acute rejections 
111 Improved graft survival, 
second rejections later 
112 No effect 
113 No effect 
114 Improved graft survival 
115,116 No effect 
Ca = Cadaver Transplantation 
R = Related Transplantation 
С = Controlled Trial 
MC = Multicenter Trial 
Abbrevations of centers: 
AEMC, Albert Einstein Medical Center 
BUH, Boston University Hospital 
CHLA, Childrens Hospital of Los Angeles 
JMC, Jefferson Medical College 
LACU, Los Angeles County University 
MGH, Massachusets General Hospital 
PBBH, Peter Bent Bngham Hospital 
TGH, Toronto General Hospital 
TWH, Toronto Western Hospital 
lack of adequate controls of transplanted patients who did not receive 
ALS. The control groups were retrospective, being those patients treat­
ed before the introduction of this agent. Although the results of the 
first studies with ALS suggested a beneficial effect, they are somewhat 
hard to interpret, because in most centers overall management of the 
transplanted patients improved during this initial period. The control­
led trials in the early years are not appropriately stratified for fac­
tors that are now known to influence graft survival (age, blood trans­
fusions, HLA-typing, etc.), and therefore, even the results of these 
trials are hard to evaluate. With these restrictions in mind it can be 
concluded that 2β centers reported of a beneficial effect of adjunc­
tive, prophylactic ALS treatment, 19 found no effect and the results of 
four centers were not conclusive. The successful results obtained with 
ALS most often regarded the occurrence of less acute rejections within 
the first three months after transplantation or the use of lower 
amounts of steroids, but without a concomitant improvement of graft 
survival. Improved graft survival was only reported by 14 centers. When 
we only consider the controlled trials, 25 could be evaluated. Nearly 
all of these controlled trials were done after 1972. The first control­
led trials were performed in Boston^ ,^, and Sidney" -^, biit both 
studies used a variable treatment schedule. The Boston group evaluated 
the ALS m both cadaveric and living related transplantations, and the 
Sydney group used both horse and goat ALS. The two groups reported a 
favourable effect. Of the 25 centers with a controlled trial 10 observ­
ed no effect at all of the ALS administration. Moreover, several con­
trolled and non-controlled studies reported on the use of ALS in both 
cadaveric and living related transplantations, which makes comparison 
between treatment groups and between different centers more difficult. 
When we confine our analysis to the controlled trials concerning cada­
veric donors only, five out of a total of 15 found no effect. If we 
narrow the criteria further by only selecting trials including more 
than 50 patients treated with ALS, one out of five showed no effect. 
Another problem in evaluating the efficacy of ALS as prophylactic agent 
was the variability in treatment schedules used. Moreover a lot of pa­
tients could not complete these schedules because of side effects, 
whereas several studies were temporarily interrupted, because of lack 
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of ALS supplies. In Table II the treatment schedules are given related 
to the final outcome of the trial. No definitely favourable schedule 
can be derived from this data. There were two centers ,°,'"2, who 
reported a favourable outcome with only five dosages of ALS. Both used 
rabbit ALS, and this brings us to the question in which species to 
raise the ALS. 
Table II. Treatment schedules with prophylactic ALS 
Treatment Schedule Number of Centers Favourable Effect 
0 - 1 week 2 2 
1 - 2 weeks 10 5 
2 - 3 weeks 13 θ 
> 3 weeks 12 7 
Variable 14 7 
Most centers used a horse ALS and about 50% reported a beneficial ef­
fect. The reports about prophylactic use of rabbit A L S 7 1 " 7 4 , 8 3 , 8 9 , 1 0 2 , 
1071114-1161 stem from six different studies. Four reported a benefi­
cial effect, while m Stockholm 1 1 5, 1 1 6 and in Birmingham (UK) 8 3, the 
results were disappointing. In the latter study ALS raised in cows and 
pigs was also used which makes it less well comparable to the others. 
Two centers used goat ALS^2, 3 , 6 5 ~ 6 9 and both reported a beneficial ef­
fect. Again, there are problems with the interpretation because one 
center also used an equine A L S 6 5 - 6 9 , and the other compared the effica­
cy of ALS raised against spleen or thymocyte lymphocytes52,53. 
One of the main problems of the use of ALS in human renal transplanta­
tion is the lack of a satisfactory in vitro test that can give a pre­
dictive index of the efficacy of the agent prior to its injection in 
man. Commercially available horse ALS can differ in potency from lot to 
lot. Rabbit ALS poses an extra problem because the preparation of large 
batches is very laborious. Therefore, different batches, that may vary 
in potency, have to be used even during a single trial. The reason that 
it is used despite this disadvantage is the evidence that the rabbit is 
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the best producer of ALS . Consequently, the amounts of protein that 
have to be administered to achieve the immunosuppressive effect are 
much lower than with horse ALS. 
There is more agreement on the route of administration of ALS. In the 
earlier reports the subcutaneous and intramuscular route were used, but 
this was very painful, especially with horse ALS of which large volumes 
(up to 20 ml) are necessary. The intravenous route is now used by near-
ly everyone. It is the most convenient route for the patient, provided 
that administration is not too rapid, because this may result in a hy-
potensive episode due to bradykinin release from the destroyed circula-
ting lymphocytes. Several clinicians prefer to inject ALS into large 
veins via an indwelling central venous catheter, but this is nearly ne-
ver necessary when rabbit ALS is used. Also the use of an arteriovenous 
fistula or shunt should be avoided. We used in nearly all patients pe-
ripheral veins, even the tiny ones in small children, and we rarely saw 
thrombophlebitis. Treatment with horse ALS requires about four times 
more IgG and probably this larger amount of foreign protein more often 
causes thrombophlebitis. 
Definite conclusions about the efficacy of ALS as an adjunctive agent 
in human renal transplantation cannot be drawn. The fact that so many 
centers did not find any beneficial effect makes it highly doubtful 
whether the approach of administering ALS from the day of transplanta-
tion is helpful in improving the results of renal transplantation. 
II. Antirejection treatment with ALS 
In contrast to the conflicting data on the use of ALS as a prophylactic 
agent in human renal transplantation, it has proved to be very effec-
tive in most studies where it was used to treat acute rejection episo-
des. The administration of ALS only at the moment of an acute rejection 
has obvious advantages as compared to a protocol of prophylactic ALS 
treatment. A considerable number of patients never experience an acute 
rejection and do not need unnecessary treatment with the foreign pro-
tein. In our department about 35% of the patients with a cadaveric 
transplant never experience a rejection, but, it is impossible to iden-
tify these patients in advance. Use of ALS as antirejection treatment 
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is also preferable because treatment from the day of transplantation 
introduces the risk that the patient has already formed antibodies 
against the foreign protein when the acute rejection occurs/ thus ma-
king its treatment less effective· 
Treatment of acute rejections with ALS has incidentally been tried sin-
ce the early days of the use of ALS in renal transplantation and seve-
ral centers have reported their results 3 5, 3 7, 3 9, 4 8, 5 6, 6 5" 6 9, 8 5, 1 1 4, 
1 1 9
. Almost all of these centers used ALS also as a prophylactic agent 
and few patients were treated with ALS for an acute rejection with va-
rying success· The centers that have performed more systematic investi-
gations on the use of ALS as antirejection treatment are given in Table 
III. They are listed chronologically according to the year that the ALS 
treatment was started. Again, centers with the same starting date are 
listed alphabetically. Of the three centers that are listed on two li-
nes 1 2 5, 126,130-1331136-1401 t h e flrst line represents all patients, 
while the second line gives data of another study in a subgroup of pa-
tients. There are only three studies in which no effect was seen. All 
other centers report some beneficial influence. This varied from fewer 
second rejections, decreased requirements of steroids, or faster rever-
sal of the serum creatinine to improved graft survival. The final out-
come of this form of treatment proved to be much more favourable than 
of the prophylactic use. As can be seen in Table III, there were 10 
centers that carried out a controlled trial, but only three of those 
tried to determine the efficacy of ALS antirejection treatment without 
a concomitant increase of steroids125,^"- , . The controlled study 
from Boston125 concerned only the treatment of acute rejections in li-
ving related donors and it might be expected that these rejections are 
more easily reversed than those of cadaveric grafts. The group from 
Cleveland used ALS also as prophylactic immunosuppressive agent for 14 
days, and this may obviously have interfered with the reaction to the 
subsequent antirejection course. Anyhow, this policy enabled them to 
use very low doses of steroids. The only prospective randomized trial 
in cadaveric transplantation with ALS as the sole antirejection treat-
ment was performed by our group13"-132. As described in the preceding 
chapters we observed not only an improved graft survival, but also a 
decrease in mortality, without a concomitant rise in side effects or 
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Table III Antirejection treatment with ALS 
Center 
Year Duration 
of No.of Treatment Steroid Specifications Adjunc-
Start Pat. (days) Resistant of Study tive 
Refe-
rences Final Outcome 
Cambridge 
Cleveland 
Odense 
Minneapolis 
New York 
Boston 
Indianapolis 
Minneapolis 
Nijmegen 
Washington DC 
1967 
1967 
¿1973 
1974 
1976 
1977 
1977 
1977 
1977 
1979 
1979 
1979 
7 
29 
14 
25 
32 
49 
10 
23 
33 
50 
6 
Θ3 
variable 
18 inject. 
21 
10 
10-21 
14 
14 
15 
10 
21 
21 
24 
N 
N 
N 
N 
Y 
N 
N 
N 
N 
N 
Y 
Y 
Ca 
Ca/R 
и 
Ca/R 
Ca/R 
Ca/R 
R 
Ca 
Ca/R 
Ca 
Ca 
Ca/R 
-
-
С 
С 
-
-
С 
с 
с 
с 
-
-
Y 
Y 
Y 
Y 
Y 
N 
N 
Y 
Y 
N 
N 
Y 
119 
43,44 
120, 
122 
123, 
125, 
125 
127, 
129 
130-
133 
134, 
121 
124 
126 
128 
•132 
135 
No effect 
No effect 
Faster reversal 
of rejection 
Fewer second 
rejections 
Improved graft 
survival 
Favourable 
Less steroids 
Improved graft 
survival 
Improved graft 
survival 
Improved graft/ 
patient survival 
Favourable 
Favourable 
Table III (continued) 
Center 
Year Duration 
of No.of Treatment Steroid Specifications Adjunc- Refe-
Start Pat. (da^s) Resistant of Study tive rences Final Outcome 
Cleveland 1980 37 
1980 11 
Detroit 1980 30 
Frankfurt/Main 1980 24 
Madison 1980 35 
Washington DC 1980 29 
Philadelphia 1982 8 
10 
10 
10 
10 
14 
10 
partly 
N 
N 
Y 
Y 
Y 
Ca/R 
Ca 
Ca 
Ca 
Ca 
Ca 
-
С 
-
-
С 
с 
Ν 
Ν 
Ν 
Υ 
both 
Υ 
136· 
137 
141 
142 
143 
135 
21 Ca/R 
-140 Favourable, also 
prophylactic 
Favourable, also 
prophylactic 
Favourable, also 
prophylactic 
Favourable (also 
plasmapheresis) 
No improvement 
Favourable, also 
prophylactic 
Improved graft 
survival 
144 
Y = Yes 
N = No 
Ca = Cadaver Transplantation 
R = Related Transplantation 
С = Controlled Trial 
U = Unknown 
infections. In our study the assignment of the patients to the diffe­
rent treatment groups was obtained with an allocation method by which 
balance was achieved in advance between factors that are known to in­
fluence graft outcome 1 4 5. This method is relatively time consuming but 
it has the important advantage that there is no imbalance in important 
risk factors between both groups at the end of the trial. A problem 
that can always disarrange the balanced randomization is the identifi­
cation of new important risk factors. In the course of our trial we en­
countered this difficulty, when the role of the DRw6 antigen became ap­
parent'4". When we analyzed the influence of the HLA-DRw6 antigen on 
graft survival in our patients we initially did not find an influence 
of DRw6. However, on more detailed analysis we could demonstrate that 
the deleterious influence of the HLA-DRw6 antigen was counterbalanced 
by the antirejection treatment with ALS' 4' -' 4'. ALS antire]ection 
treatment proved to be particularly favourable in DRw6-positive reci­
pients. Although this factor was not taken into account during the 
trial, the distribution in the groups turned out to be equal at the end 
of the trial. 
Only two centers reported on treatment with ALS raised in rabbits 
i33^42
m
 ддд
 ti l e others have used equine ALS. The group from Frankfurt 
used ALS in steroid resistant rejections and, if in the biopsy a vascu­
lar rejection was found, ALS was combined with plasmapheresis, which 
leaves our study as the only one in which rabbit ALS was systematically 
used as the sole treatment for acute rejection. Thus, the available da­
ta does not allow a comparison between rabbit and horse ALS. 
The two most frequently used treatment schedules are injections during 
10 and during 21 days. There is no indication which schedule should be 
preferred. Only the group from New York 1 2 4 reported on a comparison be­
tween the two treatment schedules and found that graft survival was the 
same, but that recurrence of rejection was more frequent in the 10 day 
schedule. Although we have used a 3 week course during the trial we 
have now switched to a 10 day course and our early results are similar 
to our previous experience. 
Another matter of debate is the adjustment of the ALS dose to penphe-
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ral T cell levels. We tried to keep the T cells between 50 and 150/mm3 
to avoid excessive immunosuppression on the one hand or undertreatment 
of the acute rejection and occurrence of second rejection on the 
other. In only one other study a dose-by-rosette protocol was used^®. 
In studies with flxed dose regimens the incidence of infectiori#* does 
not seem to be increased. Moreover, in several patients we could not 
suppress the T cells below 150/mm3, despite daily injections, while the 
rejectlons In these patients nevertheless showed a good response to the 
treatment. Therefore, a dose-by-rosette protocol is probably not essen- 
tial for optimal treatment of the patients.
One of the most striking examples of the efficacy of ALS as antirejec- 
tion treatment is its use in rejections that do not respond to the con- 
ventional treatment with steroids. With the administration of ALS in 
these patients a lot of kidneys can be saved, which otherwise would 
have been rejected. Five centers have reported on this subject and all 
have found a favourable response^3,^4f133-140f142f143_ included is 
our limited experience with six steroid resistant rejections that all 
responded to additional ALS treatment. All centers report that ALS is 
still effective if used in second and further rejections. It is also 
important to note that a second or even third course of ALS can be gi- 
ven to the same patiënt without the occurrence of serious side effects 
and often with satisfactory response. The results of ALS treatment in
«late rejections, in which vascular damage mostly predominates, are hard 
to evaluate because of the diversity of clinical pictures. Our expe­
rience in these situations is not very encouraging^33• The unanimity in 
the lltterature about the effectiveness of ALS as an agent to reverse 
acute rejections and our findings that it improves patiënt and graft 
survival lead to the conclusion that it should only be used in this way 
after renal transplantation. Use of ALS as a prophylactic treatment is 
no longer warranted.
III. Toxicity of ALS
The fears that ALS treatment would be accompanied by severe side ef­
fects such as anaphylactic reactions or opportunistic infections have 
not come true, and surprisingly few side effects have been described. 
In Table IV a summary is given of the side effects mentioned in the
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studies listed in Tables I and III and in a few other studies that 
mainly deal with adverse reactions to ALS""-^'". 
Many studies do not give any details on the toxicity of ALS or indicate 
that there were no serious adverse reactions. Moreover, many of the 
early complications of ALS therapy were due to the contamination with 
antibodies to erythrocytes, platelets, serum proteins, or collagen, but 
with a better antigen choice and better absorption techniques a lot of 
these side effects, such as anemia, thrombocytopenia, and glomerulone-
phritis due to ALS deposits, have disappeared or have become rare 
events. In our series a moderate degree of thrombocytopenia was found 
in some patients, but none of the patients developed anemia or glomeru-
lonephritis. Symptoms related to the injection site, e.g. pain, erythe-
ma, swelling, and even development of reticulosarcoma at the injection 
site, have disappeared since almost all centers have started to use the 
intravenous route. The incidence of thrombophlebitis has remained low 
even in our center where we often give the infusions into tiny veins as 
mentioned before. The most commonly observed side effect is a systemic 
reaction consisting of chills and fever. The incidence varies from 20-
100%. It occurs almost invariably during the first infusion, but some-
times it recurs with each following infusion or it appears later in the 
course of therapy after many previous uneventful infusions. The chills 
and fever are possibly the result of the massive intravascular lysis of 
circulating lymphocytes. The fever is usually not high, and it is easi-
ly controlled by temporary slowing of the infusion rate combined with 
antipyretics and antihistamine drugs. The management of the patient du-
ring the ALS infusion has been described elsewhere^' , . It is most 
important to inform the patient in advance that these side effects can 
be troublesome but are relatively innocuous. Other systemic reactions 
are less common. Arthralgias, possibly a manifestation of serum sick-
ness, occasionally occur, but in our and others' experience this does 
not necessitate termination of the ALS therapy. Very serious symptoms 
like anaphylactic shock have been rarely reported, but in none of these 
cases the anaphylaxis was convincingly proved. In the more than 100 ALS 
courses that we administered we have never seen an anaphylactic reac-
tion. We encountered the most serious problems in patients with pre-
existing overhydration. These patients developed dyspnea with broncho-
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constriction during the first infusion, and this has also repeatedly 
been reported in the littérature. We now treat these patients with RATG 
dissolved in maximally 100 ml saline solution instead of the usual 500 
ml and this has eliminated these reactions. 
Although these patients theoretically run an increased risk due to 
stronger immunosuppression achieved by ALS, a significant increase in 
bacterial sepsis associated with ALS therapy has not been reported. 
There are however several reports of an increased incidence of cytome-
galovirus (CMV) infection, Epstein-Barr virus excretions, fungal infec-
tions, and herpes simplex infections during ALS treatment. It should be 
born in mind, however, that in nearly none of the patients ALS was gi-
ven as the sole drug, and therefore many side effects observed in pa-
tients might be due to the other immunosuppressive agents or to the 
combination of the agents with ALS. An argument for this is the obser-
vation of Rubin et al^'3, who found that the incidence of CMV infec-
tions did not increase in ALS treated patients, if the concomitant con-
ventional therapy had been halved. Our own observation that the inci-
dence of CMV infections was not increased, when ALS is given as the 
sole drug for rejection, fits with this concept1^2. 
Early studies also made mention of deposits of ALS, particularly horse 
ALS, in the kidney and in some cases this gave rise to the development 
of a nephrotic syndrrme. This complication was probably caused by anti-
bodies against basement membranes that contaminated the early prepara-
tions. The deposits of ALS never led to serious impairment of renal 
function, and with better purification procedures of ALS this side ef-
fect has disappeared. The incidence of neoplasms is approximately 80 
times higher in renal transplant patients than in the average popula-
tion^'^. This is probably related to the state of immunosuppression. 
One of the agents implicated was ALS , 1 6 , 1 6 2, and its role is clear 
with regard to the development of reticulosarcomas at the site of in-
jection, when ALS was given intramuscularly44,1^9, 1 6 0. It was also 
thought to cause lymphoid hyperplasia 1^ 1, 1 б 3, 16 4. Later analyses by 
Penn et al could not substantiate the suspicion that ALS plays a major 
role in the genesis of neoplasms 1' 4 -"". In the five years that we had 
used ALS none of our patients had developed a tumor, while the overall 
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Table IV Complications of ALS treatment
Side effects References
Hematologie Complications 
Anemia
Thrombocytopenia
Infectious Complications
Cytomegalovirus infections 
Epstein-Barr virus excretion 
Fungal infections 
Herpes simplex infections
Local Reactions at Injection Site 
Infection
Pain, swelling, erythema 
Phlebitis
Oncogenic Complications 
Local tumor growth 
Malignant lymphoma 
Pseudolymphoma
Renal Complications 
Deposits of ALS 
Nephrotic syndrome
150
2,37,47,48,63,65,66,69,70,78­
82,84,86,92,93,96,97,110,111, 
119,126,141,142,150
114,151,153 
125,154 
155-157 
126,144,151
35,47
1,27,33,34,36,39,43,44,47-50, 
64-66,69,73,75,92,101,115,158 
2,37,39,81,91,92,96-98,112,113, 
130-132,142
f -i44,159,160 
40,161,162 
161,163,164
70,150,165-167 
84,168
84
Table IV Complications of ALS treatment 
Side effects References 
Hematologic Complications 
Anemia 
Thrombocytopenia 
150 
2 .. J"', 47, 48 .. 63 , 65 , 66,64 , 70 , 78-
8 2, В 4, η β, rJ ¿ , 9 Τ, 9 6, 9 7, 1 1 0, 111, 
119, Ι?6.. 141, 142, 1Ь0 
Infectious Complications 
Cytomegalovirus infections 114,151,153 
Epstein-Barr virus excretion 125,154 
Fungal infections 155-157 
Herpes simplex infections 126,144,151 
Local Reactions at Injection Site 
Infection 
Pain, swelling, erythema 
Phlebitis 
35,47 
1 , 27 , 33 , 34 . 36 , 39 , 43 , 44 , 47-50 , 
6¿-&6,69,73,75,92,101,115,158 
2,37,33,SI.91.92,96-98,112,113, 
130-132, 1-,2 
Oncoganic Complications 
Local tunor growth 
Malignant lymphoma 
Pseudolymphoma 
4<,159,ih0 
4 Э , 16 i . 'ι С 2 
lo". , 1 ^ 3 , K-.4 
Renal Complications 
Deposits of ALS 
Nephrotic syndrome 
70, 1Ξ0. 1'J5-1O7 
84, 168 
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Table IV (continued) 
Side effects References 
Systemic Reactions 
Anaphylaxis 
Arthralgia 
Chills 
Dyspnea 
Epidemal necrolysis 
Fever 
Hypotension 
Lumbar pam 
Periorbital edema 
Pruritus 
Rash 
Sei '_?* si^K.i J S 
Tac 1, / c a r d i a 
U r t i c a » i a 
2 7 , 3 3 , 3 7 , 3 9 , 4 2 , 4 4 , 1 1 5 , 1 2 7 , 1 2 8 , 
158 
3 7 , 3 9 , 6 6 , 6 7 , 7 5 , 8 0 , 9 1 , 9 2 , 1 0 9 , 
1 2 5 , 1 3 0 - 1 3 2 , 1 4 1 , 1 4 2 , 1 5 8 
1 , 2 , 2 6 , 2 7 , 3 4 , 3 6 , 3 7 , 3 9 , 4 8 , 4 9 , 6 3 , 
7 0 , 7 8 - 8 1 , 8 4 , 9 2 , 9 3 , 1 0 9 , 1 1 1 , 1 1 5 , 
1 1 3 , 1 2 5 , 1 3 0 - 1 3 2 , 1 4 1 , 1 5 0 , 1 6 9 
З"
1
, 3 3 , 4 8 , 6 6 , 7 L , 3 0 , 9 8 , 1 1 3 , 130-
132 
i g o 
1 , 2 , 2 6 , 2 7 , 3 4 , 3 6 , 3 7 , 3 9 , 4 7 - 5 0 , 5 3 , 
57 ,63 , 64 , 67 , 69 , 70 , 73 , 75 , 78-82 , 
8 4 , 8 6 , 9 1 - 9 3 . . 1 0 1 , 1 0 9 , 1 1 1 , 1 1 3 , 
1 1 5 , 1 1 8 , 1 2 5 - 1 2 8 , 1 3 0 - 1 3 3 , 1 3 5 , 
1 3 6 , 1 4 1 , 1 4 2 , 1 5 8 , 1 6 9 
26 , 34 , 36 , 43 , 44 , 48 , 86 , 92 , 11 5 
37,39,57,31,92,130-132 
1,81,158 
2.37,39,43,44,30,82,91,92,111, 
158 
2 36,37,39,47,57,76,81,82,91, 
'J2, 111 . íSC, M'ì 
1,2,4,36,53,61,75,78,84,91,130-
133, 170 
3^ ,';^ , 130, 113 
1 , 27 , 36 , 43 , 45 , 46 , 50 , 57 , 39 , 63 , 
66,75,79,82,84,91,^2,96,97, 
100, 113,130-132,1^8 
incxdence of tumors in our renal transplantation programme is 2.8% 
In summary, we may conclude that severe toxicity from ALS treatment has 
not been reported. A lot of the earlier described complications have 
disappeared. We have not been forced to discontinue a single ALS course 
because of the side effects. The safety of ALS treatment is once more 
confirmed by our finding that repeated ALS courses could be given with­
out major adverse reactions. 
IV. Monoclonal antithymocyte globulins 
Although ALS has proved to be highly efficacious in reversing an acute 
rejection m renal transplantation, the agent has some drawbacks. ALS 
not only contains a heterogeneous group of antibodies to human Τ cells, 
but also a hi9h amount of other irrelevant antibodies. In comparison to 
the less specific immunosuppressive agents like azathiopnne and pred­
nisone humoral immunity is probably less impaired, but the patient un­
der ALS treatment is still vulnerable to viral and fungal infections. 
Furthermore, the potency of the ALS can vary from batch to batch and a 
consistent product cannot be guaranteed. Therefore, the search for more 
specific agents has continued. Thanks to the development of the hybri-
doma technique"" monoclonal antibodies to human Τ cells can now be 
produced. The preparations are completely standardized and not contami­
nated by irrelevant antibodies. The purpose of this section is to give 
a short overview of the in vitro and in vivo results obtained with mo­
noclonal anti Τ cell antibodies. Additional information can be found in 
some reviews on this subject^1*, ° . 
In vitro results 
It has been postulated that monitoring of the peripheral Τ cell levels 
might provide a reliable measure of the adequacy and safety of an immu­
nosuppressive therapy. Many investigators have used monoclonal antibo­
dies to monitor the peripheral Τ cell levels before and after renal 
transplantation and although some groups claimed that Τ cell levels,le­
vels of Τ cell subsets, or Τ cell subset-ratios can be used to predict 
the occurrence of a rejection, most of the studies report rather con­
flicting data'*", some agreement has now been reached with regard to 
the relation of the Τ helper/T suppressor ratio to allograft function. 
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Patients with a high ratio were likely to suffer at least once from an 
acute rejection, but the ultimate outcome was excellent, while patients 
with a low ratio were less likely to have an acute rejection, but if it 
occurred, the ultimate outcome was bad. This rule is, however, not va­
lid in patients treated with cyclosporin A. The Τ helper/T suppressor 
ratio is probably also indicative for the presence of CMV infection. 
These patients mostly have a very low ratio, and this might be useful 
to discriminate between CMV infection and rejection^"3. jjy monitoring Τ 
cell levels with the AET-rosette technique, we could neither predict an 
acute rejection nor the ultimate outcome of the graft. This is not so 
surprising, since the immune response is regulated by distinct Τ cell 
subsets and important changes in one or several subsets may not be re­
flected in the total Τ cell count. We have also performed some studies 
to investigate the role of the Τ cell subsets determined with the OKT 
monoclonal antibodies. The results were disappointing and we could not 
confirm the findings of other investigators. The number of lymphocytes 
obtained from heavily immunosuppressed patients, and particularly from 
ALS treated patients, were often very low, and the lymphocytes obtained 
from patients by separation techniques were mostly so heavily contami­
nated with non-lymphocytes that a proper determination of Τ cell sub­
sets was impossible. In using whole blood samples of these patients we 
furthermore found that the red blood cells were highly resistant to ly­
sis, so that purified leukocyte suspensions could not be obtained with­
out gradient centnfugation. Many of the conflicting data reported in 
the littérature may be due to these technical difficulties. We found 
great day to day fluctuations in the values of the same patient. We 
were therefore not able to use the Τ cell subset levels to predict the 
occurrence of rejection or the outcome of the graft. Discrimination be­
tween CMV infection and rejection was also impossible in our hands. 
In vivo studies 
Before the monoclonal antibodies against Τ cells could be used in a 
clinical situation, an evaluation of their immunosuppressive potency 
and toxicity in animal studies was required. Because the monoclonal an­
tibodies were so specifically directed against human Τ cells, only some 
reacted with Τ cells of non-human primates, and could be tested in 
these models. In Table V the studies in monkeys with monoclonal antibo-
87 
dies against different human T cell populations are summarized. The 
first study was done by Cosimi et al18®, who tested an antibody against 
T helper cells in Cynomolgus monkeys carrying a renal allograft. Only a 
minute amount of antibody (17-51 mg/recipient) was necessary to obtain 
an improved graft survival. This beneficial effect was achieved without 
a concomitant decrease of the total T cells, while the helper T cells 
gradually decreased (from +_ 800 to + 250/mm^). Bieber et al18^  found a 
profound decrease of T cells in three monkeys treated with a pan T cell 
antibody. One of the monkeys also received a skin graft, which showed a 
significantly prolonged survival. From Table V the main drawbacks of 
these monoclonals can also be seen. Although not all investigators re- 
ported on the incidence of antibody formation against mouse IgG, it was 
apparent that antibodies very often developed and this interfered with 
the effectiveness of the treatment. Other problems were the occurrence 
of T cell coating and antigenic modulation. Antibody-coating is a phe- 
nomenon in which cells have obviously bound the monoclonal antibody, 
but this does not result in clearance of these cells from the circula- 
tion. The most likely explanation is that the antibody does not lead to 
an effective opsonization of the coated cell due to its low density on 
the cell membrane or because it belongs to a subclass that cannot bind 
to the recipients opsonizing system. Antigenic modulation is a reversi- 
ble loss of specific membrane antigens due to internalization or shed- 
ding of the antigen after binding of the monoclonal antibody. A few 
days after cessation of monoclonal antibody administration the specific 
membrane antigen towards the monoclonal antibody is directed will reap- 
pear. The inhibitory role of modulation and coating during monoclonal 
antibody therapy is not quite clear, since several investigators repor- 
ted a beneficial effect despite the occurrence of modulation or coa­
ting18®,188, while in another report there was no improvement of graft 
survival when these phenomena were observed187. Generally, the animals 
did not show serious side effects, although Billing18  ^reported on four 
subsequent lethal events, when he administered high intravenous doses 
of an anti-Ia-like antibody. The mechanism of this lethal effect is un- 
known, but is probably related to the specificity of this monoclonal 
antibody and not to an anaphylactic response to mouse protein, since 
treatment with smaller doses did not lead to serious problems.
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Table V Preclinical use of monoclonal anti T-cell antibodies
Investigators
No. of 
Reci- 
pients
Monoclonal
Antibody
Against
Treatment 
Schedule 
(clays)
Antibody
Formation
(No.)
Coating
(No.)
Modu-
lation
(No.) Final Out□ome
Bieber et
a l  184 3 Total T cells 1 dose ? ? ? Profound fall of T cells
Billing et 
a l « 5
9 Ia pos cells 14? ? ? ? Improved skin 
graft survival
6 Blast cells 
and monocytes
14? ? ? ? Improved skin 
graft survival
Cosimi et 
al186
10 Helper T cells 7-14 ? + ? Prolonged kidney 
graft survival
Giorgi et al^®^ 3 Total T cells 12-14 3 + + No effect
Jonker et 
al1BB
6 Helper T cells 14 6 4 0 Improved skin 
graft survival
4 Suppressor T 
cells
14 4 2 0 No effect
4 ■“-vTotal T cells 14 4 0 4 Improved skin 
gi aft survival
(+); has been reported, but number of monkeys unknown
In summary, these animal studies indicate that monoclonal antibodies 
can be administered without serious side effects and that most of the 
monoclonals directed against Τ cells exerted an evident immunosuppres­
sive effect. 
Encouraged by the ease of administration, the effectiveness, and the 
lack of toxicity of monoclonal antibody therapy in nonhuman primates, a 
few centers started to evaluate the efficacy of monoclonal antibody in 
human renal transplantation (Table VI). Cosimi et al. were the first to 
report on a clinical trial with a monoclonal antibody against total Τ 
cells and they used it to treat acute rejections. Although they observ­
ed reversal of acute rejection in all cases, their results were some­
what disappointing, because almost all patients suffered from a subse­
quent rejection and developed antibodies against mouse IgG. In the 
other studies all but one^'^ used a monoclonal against total Τ cells. 
Takahashi et al used an antiblast monoclonal antibody which was effec­
tive against proliferating Τ cells and did not depress Τ cell levels. 
Although this monoclonal reacted also with stem cells in bone-marrow, 
and with monocytes they found no serious side effects and could reverse 
acute rejections in 90 percent of the cases. Interestingly, the only 
monoclonal that did not produce modulation or antibody formation was 
not effective in reversing renal allograft rejection^1". This antibody 
was of the IgG2b subclass. We suspect that this was the reason why it 
was ineffective because there is preliminary evidence from our labora­
tory that monocytes of almost all human individuals cannot bind the Fc 
fragment of mouse IgG2b resulting in lack of removal of antibody coated 
cells (W. Tax, personal communication). 
Most of the antibody response of the recipient is probably not directed 
against allotypic determinants but against the idiotype of the monoclo­
nal antibody. The development of antudiotypic antibodies after mono­
clonal therapy was nicely demonstrated by Cosimi's groupe". There is 
now evidence that repeated injections of monoclonal antibodies in the 
presence of circulating antudiotypic antibodies do not lead to anaphy­
lactic or other allergic reactions. The inhibitory effect of the anti-
idiotypic antibodies can therefore easily be overcome by administering 
higher doses of monoclonal antibodies (P. Capel, personal communica-
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Table VI Clinical use of monoclonal anti T-cell antibodies in renal transplantation 
Investigators 
Treatment Schedule Anti- Anti-
No.of Isotypic Idiotypic 
Pat. Mode Duration Antibodies Antibodies 
(days) 
Antigenic 
Modu­
lation Final Outcome 
Chatenoud et a l 1 8 9 6 14 Profound 
decrease of Τ 
cells 
Cosimi et a l 1 9 0 , 1 9 1 8 
Takahashi et a l 1 9 2 19 
variable Reversal of all 
re]ections 
Beneficial 
effect 
Thurlow et al 193 10 No effect 
P,- Prophylactic, T; Therapeutic 
tion). Modulation also occurs after injection of monoclonal antibodies 
in man. Until now, this has only been demonstrated after injection of 
0KT3 antibody^89-191f195# The consequences of this phenomenon in the 
clinical situation are not yet clear.
Chills and fever invariably occurred following the first or s'«feond in- 
■ “« ufusion of monoclonal antibody, but were usually not noted during subse-
quent infusions, suggesting rapid cell lysis as the etiology of this
toxicity. Other side effects were not noted.
In summary, the results of monoclonal anti T cell antibody therapy in 
human renal transplantation are until now not very impressive. Most re- 
jections could be treated, but rapid subsequent rejections and the de- 
velopment of antibodies pose an extra problem. Clinical trials with 
other monoclonal antibodies and particularly with combinations of mono- 
clonal antibodies will give a more definite answer with regard to effi- 
cacy of monoclonal antibodies in renal transplantation. Monoclonal an­
tibodies that are active against proliferating T cells such as the an­
tibody described by Takahashi et al ^ 2 are of special interest, because 
they will specifically eliminate those cells that are triggered by the 
MHC antigens of the donor. In our laboratory, Tax recently has develop- 
ed an antibody (WT1) that is specifically reactive with all T cells. He 
has shown that the expression of the antigen against which it is direc- 
ted shows a large increase on proliferating T c e l l s wrl an­
tibody has already been shown to have immunosuppressive activity since 
it can prolong skin graft survival in Rhesus monkeys188. The antibody 
is an obvious candidate for clinical application, and we are currently 
preparing it for a human pilot study, in which we will use it for the 
treatment of acute rejection.
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SAMENVATTING 
Niertransplantatie is een algemeen geaccepteerde vorm van behandeling 
van terminale niennsufficientie geworden met grote kans op volledige 
revalidatie van de patient. De uremische patient, die aangewezen is op 
behandeling met chronische dialyse wordt niet alleen in zi]n doen en 
laten beperkt door de steeds terugkerende dialysen, maar moet zich bo­
vendien nog onderwerpen aan dieet- en vochtbeperking terwijl zi]n alge­
mene conditie desondanks meestal verre van optimaal blijft. De resulta­
ten van niertransplantaties zijn na een aanvankelijke, sterke verbete­
ring, de laatste jaren op hetzelfde niveau gebleven. De voornaamste 
oorzaak van een mislukte transplantatie is de onbehandelbare rejectie. 
Als immunosuppressleve middelen zijn door de jaren heen steeds Predni­
son en azathioprine gebruikt, terwijl acute rejecties practisch altijd 
behandeld werden met verhogen van de steroid-dosis. Met deze middelen 
kunnen niet alle rejecties afdoende gecoupeerd worden, terwijl er an­
derzijds wel veel ernstige bijwerkingen optreden als gevolg van de al­
gemene vermindering van de afweer. Om de resultaten van niertransplan­
taties te verbeteren zijn sterkere en liefst ook meer specifieke immu-
nosuppressieve middelen nodig. De cel, die een centrale plaats inneemt 
bij een acute afstoting is de T-lymfocyt. Eliminatie van Τ cellen door 
antilymfocytenserum (ALS) zou, althans in theorie, een meer specifieke 
therapie kunnen zijn ter voorkoming en behandeling van acute rejecties. 
ALS is al een oud middel. Vanaf het begin der zestiger jaren is uit 
veel dierproeven gebleken dat ALS de transplantaatoverleving kan ver­
lengen. Vanaf 1967 is ALS klinisch gebruikt als immunosuppressief mid­
del, in eerste instantie direct in aansluiting aan de transplantatie om 
het ontstaan van rejecties te voorkomen. Het effect van deze vorm van 
behandeling was minder gunstig dan men op grond van de resultaten ver­
kregen in de dierproeven zou mogen verwachten. Bovendien werd beoorde­
ling vaak bemoeilijkt, doordat adequate controlegroepen ontbraken. In 
de laatste jaren kwamen er uit enkele oriënterende studies aanwijzingen 
dat ALS mogelijk meer geschikt was voor de behandeling van manifeste 
rejecties dan voor de profylaxe ervan. Ook hier bleef het trekken van 
verantwoorde, definitieve conclusies onmogelijk door het ontbreken van 
gecontroleerde studies. In een poging de resultaten van de mertrans-
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plantaties te verbeteren en tegelijkertiid de effectiviteit van ALS als 
antirejectiemiddel te testen, zijn we in 1979 gestart met een onder-
zoek, waarbij behandeling met ALS zonder verhoging van de steroid-dose-
ring werd vergeleken met de conventionele antirejectiebehandeling be-
staande uit hoge doseringen prednison. Een van de basis-eisen van het 
onderzoek was de aanwezigheid van een adequate controle-groep en daarom 
is vanaf het begin in overleg met de Mathematisch-Statistische Advies-
af deling (MSA) gestreefd naar een evenwichtige verdeling van de patiën-
ten in de twee behandelingsgroepen. De patiënten werden gerandomiseerd 
zodra een acute re]ectie was opgetreden waarbij rekening werd gehouden 
met alle risicofactoren, waarvan bekend is dat ze van belang zijn voor 
de transplantaatoverleving. Voor de factoren die al bekend waren op het 
moment van transplantatie was dat niet zo'η probleem, maar een drietal 
factoren kon pas vastgesteld worden op het moment dat de diagnose re-
jectie gesteld werd (interval tussen transplantatie en rejectie, tijd­
stip van laatste hemodialyse en lichaamstemperatuur van de patient). 
Aangezien de MSA in het algemeen niet onmiddellijk geconsulteerd kon 
worden, als een rejectie werd vastgesteld, moest voor een juiste rando-
mizatie van de patiënten een nieuwe procedure ontwikkeld worden. Zo 
snel mogelijk na een transplantatie werden de bekende risicofactoren 
doorgegeven aan de MSA, die de patient randomiseerde voor die factoren 
en een achttal gesloten enveloppen plaatste op de verpleegafdeling met 
al de mogelijke combinaties van de nog niet bekende risicofactoren. Op 
het moment van rejectie werd dan de passende envelop geopend waarin de 
voorgeschreven antirejectiebehandeling stond vermeld. Op die - zij het 
nogal tijdrovende - manier waren we bij de start van het onderzoek al 
verzekerd van een juiste verdeling van de risicofactoren. 
Toegelaten tot het onderzoek werden alleen patiënten die een cadaver-
nier hadden ontvangen en een acute rejectie kregen binnen 3 maanden na 
niertransplantatie. Deze laatste voorwaarde was nodig aangezien alleen 
cellulaire rejecties behandeld zouden worden en de kans dat de rejectie 
vasculair is na drie maanden sterk toeneemt. De antistof die we ge-
bruikt hebben, werd bereid in het Rijks Instituut voor de Volksgezond-
heid door immunisaties van konijnen met menselijke thymocyten. Via en-
kele zuivenngsstappen werd uit het serum van de geïmmuniseerde dieren 
de globuline fractie verkregen (ATG). Tijdens een antirejectiebehande-
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ling werd het ATG intraveneus toegediend gedurende 3 weken, waarbij een 
zogenaamd "dose-by-rosette" protocol werd gebruikt. Bij een dergelijk 
protocol wordt getracht de perifere Τ cellen - bepaald met de rosette 
test - binnen bepaalde grenzen te houden door de ATG dosering aan te 
passen. De gehanteerde onder- en bovengrens voor de T-cellen waren res­
pectievelijk 50 en 150 per mm 3. Beneden de ondergrens zouden meer in­
fecties voorkomen door te sterke immunosuppressie, terwijl erboven de 
kans op rejectie zou toenemen. Tijdens ATG-therapie werd de prednison-
dosis niet verhoogd, om de schadelijke bijwerkingen van hoge doseringen 
Prednison zoveel mogelijk te vermijden. 
Na bijna vier jaar werd het onderzoek afgesloten toen 50 patiënten met 
een acute rejectie behandeld waren met ATG en 50 patiënten in de con-
trolegroep met hoge doseringen Prednison. De Τ cellen waren gedurende 
ATG-therapie in de meeste gevallen gemakkelijk binnen de gestelde gren­
zen te houden. In de ATG-groep werd dan ook een significante daling van 
de Τ cellen gevonden tijdens de antirejectietherapie, terwijl in de 
prednison-groep er geen verandering ontstond in het T-cel-niveau. De 
uiteindelijke transplantaat- en patientoverleving, bepaald een half 
jaar na het beëindigen van het onderzoek, was significant beter in de 
ATG-groep dan in de groep behandeld voor acute rejectie met hoge dose-
ringen Prednison. Het aantal tweede rejecties was lager in de ATG-
groep. Als er een tweede rejectie in de ATG-groep optrad, dan gebeurde 
dat later dan bij de patiënten uit de prednisongroep. Bovendien ont-
stond de daling van het serumkreatininegehalte sneller in de ATG-
groep. Ook patiënten met een tweede rejectie (overigens meestal behan-
deld buiten het protocol), bij wie de eerste rejectie behandeld was met 
hoge doseringen prednison, konden afdoende behandeld worden. Met name 
was ATG ook effectief bij de behandeling van de Steroid-resistente re-
jecties. Dit waren de rejecties die in het geheel niet of zeer onvol-
doende reageerden op conventionele therapie met Steroiden. In alle ge-
vallen kon het transplantaat behouden blijven na aanvullende ATG thera-
pie. Minder effectief was ATG in de behandeling van vasculaire rejec-
ties. Hoewel deze patiënten (buiten protocol) aanzienlijk meer ATG kre-
gen, lukte het niet om het aantal Τ cellen voldoende te doen dalen en 
was de reactie op de therapie voor wat betreft de nierfunctie eveneens 
erg matig. Overigens werden bij geen enkele ATG behandeling ernstige 
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bijwerkingen gevonden en in geen enkel geval moesten we de therapie 
staken wegens bijwerkingen. Infecties kwamen in beide groepen even vaak 
voor. De gemiddelde nierfunctie van de patiënten met een nog functione-
rend transplantaat was gelijk in beide groepen. Uiteraard was de cumu-
latieve steroiddosering in de eerste drie maanden significant lager in 
de ATG-groep dan in de prednisongroep.Mogelijk als gevolg hiervan was 
het aantal gevallen van avasculaire botnecrose in de ATG-groep lager. 
Een risicofactor die pas in de loop van het onderzoek duidelijk werd, 
was de aanwezigheid van het DRw6-antigeen bij de ontvanger. In enkele 
mededelingen in de literatuur werd er op gewezen dat DRw6-positieve 
ontvangers een significant slechtere transplantaatoverleving zouden 
hebben dan DRw6-negatieve patiënten. Analyse van 223 transplantaatont-
vangers in ons centrum liet geen invloed van het DRw6-antigeen zien op 
de transplantaatoverleving, maar wel vonden we significant meer rejec-
ties in de DRw6-positieve groep. Er was dus ook in onze populatie moge-
lijk een DRw6 effect, maar dit vond blijkbaar niet zijn neerslag in 
slechtere transplantaatoverleving. Het leek waarschijnlijk dat de aard 
van de antirejectie therapie hierbij van belang was. Inderdaad bleek 
het effect van antirejectie therapie met ATG significant beter dan dat 
van prednison in de DRwö-positieve patiënten, terwijl in de DRwö-nega-
tieve groep de verschillen veel minder uitgesproken waren. Wanneer de 
met ATG behandelde patiënten buiten de analyse gehouden werden, dan 
werd de ongunstige invloed van het DRw6-antigeen op de transplantaat-
overleving ook bij onze patiënten zichtbaar. Omdat bij analyse achteraf 
bleek dat het DRw6-antigeen gelijk verdeeld was over beide behande-
lingsgroepen in het gerandomiseerde onderzoek leidde de identificatie 
van deze nieuwe risicofactor niet tot veranderingen in onze oorspronke-
lijke conclusies. 
Antirejectiebehandeling met konijnen-ATG is dus superieur aan de con-
ventionele therapie met hoge doseringen prednison. De transplantatiere-
sultaten verbeteren sterk zonder dat deze blijkbaar krachtiger vorm van 
immunosuppressie leidt tot een vermindering van de afweer tegen infec-
ties. Met name bij DRw6-positieve patiënten is de ATG-behandeling ef-
fectief in vergelijking met prednisonverhoging. Ook tweede en steroid-
resistente rejecties kunnen uitstekend behandeld worden met ATG. 
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met behulp van de Hemalog-D werd vakkundig uitgevoerd door Paul Ruys en 
Harne Louwers van de afdeling hematologie. Jacqueline Hagemann en 
Peter Faaber namen de vele werkzaamheden rond de bepaling van de ATG 
spiegels en de anti ATG titers voor hun rekening. Het engelengeduld van 
Henk van Lier van de Mathematisch Statistische Adviesafdeling tijdens 
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STELLINGEN 
1. Een acute rejectie van een mertransplantaat kan het beste behandeld wor­
den met antilymfocytenglobuline. 
2. Het gebruik van antilymfocytenglobuline ter voorkoming van acute rejec-
ties van mertransplantaten is obsoleet. 
3. De incidentie van acute rejecties is bij DRw6-positieve transplantaatont-
vangers verhoogd. Desalniettemin kan door behandeling van deze rejecties 
met antilymfocytenglobuline een slechtere transplantaatoverleving voor­
komen worden 
4. Acute transplantaatrejecties die met of slecht reageren op hoge doses 
Prednison, kunnen in het merendeel van de gevallen wel goed bestreden 
worden door een aanvullende behandeling met antilymfocytenglobuline. 
5. Het metabole defect bij cystmune kan hersteld worden door een nier­
transplantatie. 
Hoitsma AJ, Koene RAP, Tnjbels FJM, Monnens 
LAH Disappearance of cystinuna after renal trans­
plantation JAMA 1983, 250 615 
6. Matige hydratie van de ontvanger in combinatie met toediening van 
mannitol maakt postoperatieve tubulusnecrose na niertransplantatie tot 
een zeldzame complicatie. 
7. Het therapeutisch effect van monoclonale muize-antistoffen bij de mens 
wordt met zozeer bepaald door het complement-activerend als wel door 
het Fc-receptor bindend vermogen van de betreffende subklasse. 
Tax WJM, Willems HW, Reekers P, Capel PJA, Koene 
RAP Polymorphism m mitogemc effect of IgGl mo­
noclonal antibodies against ТЗ antigen on human Τ 
cells Nature 1983,304 445 
8. De vrees dat bij merdonoren op langere termijn nierfunctiestoornissen 
zullen ontstaan door een focale segmentale glomerulosclerose in de res­
terende nier, lijkt ongegrond. 
Hoitsma AJ, Paul LC, van Es LA,Koene RAP Long­
term follow-up of living kidney donors, a two cen­
tre study Neth J Medicine 1984, in press 
9 Bij dialysepatientcn met gestoorde blaasfunctie kan een mertransplantaat 
zonder problemen worden aangesloten op een ileocutaneostomie 
Arenasen HJ, Hoitsma AJ, Debruyne PMJ Nier-
transplantatie bij patiënten met een uiineweg-om-
leiding Ned Τ Geneesk 1984, in druk 
10 Een sterke, maar m ernst wisselende proteinune bij een normaal serum 
albumine kan wijzen op de aanwezigheid van lichaamsvreemd eiwit in de 
urine 
Hoitsma AJ, Koene RAP, Raes BCM Pathomimie 
met afwijkingen in de urine Ned Τ Geneesk 1982, 
126 2281-2283 
11 Wil de volleybalsport zeker bij de mannen — weer een enigszins aardig 
kijkspel worden, dan zullen er lengteklassen ingesteld moeten worden 
12. Het valt te betreuren dat de meeste Nederlanders met de Friese vlag alleen 
hun koffie op smaak brengen. 
Nijmegen Andnes Hoitsma 


